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ABSTRACT
Midbrain dopamine neurons exert a powerful infl uence on behavior and their dysfunction is 
associated with many neurological and neuropsychiatric diseases, including Parkinson’s disease 
(PD). Dopamine neurons are large, complex and sensitive cells. Hence, their survival and correct 
function requires coordinated action of various transcription and regulatory factors both during 
development and aging. Potentially, one such factor is glial cell line-derived   neurotrophic 
factor (GDNF). Ectopically applied GDNF is best known for its potent ability to protect and 
restore damaged dopaminergic neurons both in vitro and in vivo. GDNF-based therapies have 
been tested in clinical trials with PD patients with variable success. However, the function 
of endogenous GDNF in brain dopamine system development, aging and disease is poorly 
understood. Improvement in GDNF-based therapies requires better understanding of the 
physiological functions of GDNF in the brain.
Th e current knowledge of endogenous GDNF function remains obscure, mainly due to the 
lack of proper animal models. Th e present study investigated the regulatory role of endogenous 
GDNF in the development, maintenance and function of midbrain dopamine neurons utilizing 
novel mouse models:  GDNF conditional knock-out (cKO) mice and GDNF hypermorphic 
(GDNFh) mice over-expressing GDNF from the endogenous locus. GDNF cKO mice enable 
GDNF deletion solely from the central nervous system during embryonic development or later in 
adulthood, preserving its vital role in kidney development. Midbrain dopamine systems of these 
new mouse strains were studied with immunohistochemical, neurochemical, pharmacological, 
behavioral and molecular biology methods.
We found more substantia nigra dopaminergic cells and elevated striatal dopamine levels 
in immature and adult GDNFh mice. In cKO mice, dopamine levels and cell numbers were 
unaltered, even upon aging, and regardless of the timing of GDNF deletion. Both mouse strains 
exhibited enhanced dopamine uptake, while responses to amphetamine were augmented in 
GDNFh mice and reduced in cKO mice. GDNFh mice also released more dopamine and GDNF 
elevation protected them in a lactacystin-based model of PD. Overall, dopamine neurons were 
more sensitive to moderate elevation than complete absence of endogenous GDNF, which 
suggests that they can adaptively compensate for GDNF loss. Th is highlights the limitation of 
broadly utilized gene deletion approaches in analyzing gene function.
Our results indicate a clear role for endogenous GDNF in midbrain dopamine neuron 
development and function, but also demonstrate that GDNF is not required for their maintenance 
during aging. Furthermore, the ability of endogenous GDNF to protect animals in a PD model 
without the side eff ects associated with ectopic GDNF application suggests that elevation in 
endogenous GDNF levels may be an important future route for PD therapy.
TIIVISTELMÄ
Aivojen dopamiinihermosoluilla on voimakas vaikutus käyttäytymiseemme ja niiden 
toimintahäiriö onkin liitetty moniin neurologisiin ja psykiatrisiin sairauksiin, kuten Parkinsonin 
tautiin. Dopamiinineuronit ovat suuria, monimutkaisia ja herkkiä soluja. Tämän vuoksi 
niiden selviytyminen ja oikeanlainen toiminta niin yksilönkehityksen kuin koko elinkaaren 
ajan on riippuvaista useiden erilaisten säätelytekijöiden oikeanlaisesta yhteistoiminnasta. 
Mahdollisesti eräs tällainen säätelytekijä on gliasolulinjaperäinen hermokasvutekijä eli GDNF. 
GDNF:llä on osoitettu olevan hyvin poikkeuksellinen kyky suojella ja korjata vaurioituneita 
dopamiinihermosoluja sekä solu- että eläinmalleissa. GDNF-peräisiä lääkehoitoja onkin 
tutkittu kliinisissä kokeissa Parkinsonintautipotilailla, vaihtelevin tuloksin. Tästä huolimatta 
endogeenisen, eli aivojemme itse valmistaman, GDNF:n toiminta yksilönkehityksen, 
vanhenemisen ja sairauksien yhteydessä tunnetaan yhä huonosti. Tehokkaampien GDNF-
pohjaisten hoitojen kehittäminen edellyttää parempaa ymmärrystä GDNF:n fysiologisista 
toiminnoista aivoissa.
Endogeenisen GDNF:n toimintojen heikko tuntemus johtuu ensisijaisesti kunnollisten 
eläinmallien puuttumisesta. Tässä työssä tutkimme endogeenisen GDNF:n roolia keskiaivojen 
dopamiinihermosolujen kehityksessä, ylläpidossa ja toiminnassa käyttäen uusia eläinmalleja: 
konditionaalisesti poistogeenisiä (conditional knock-out; cKO) GDNF hiiriä sekä GDNF 
hypermorfi sia (GDNFh) hiiriä, jotka tuottavat normaalia enemmän endogeenistä GDNF:ää. 
cKO hiiriltä GDNF voidaan sikiövaiheessa poistaa täysin ainoastaan keskushermostosta tai 
vaihtoehtoisesti vasta myöhemmin aikuisilta eläimiltä. Näin säilytetään G DNF:n elintärkeä 
rooli munuaisten kehityksessä. Tutkimme näiden uusien hiirikantojen keskiaivojen 
dopamiinijärjestelmiä immunohistokemiallisten, aivokemiallisten, farmakologisten, 
molekyylibiologisten sekä erilaisten käyttäytymismenetelmien avulla.
Havaitsimme sekä hyvin nuorten että aikuisten GDNFh hiirten aivoissa kohonneen määrän 
dopamiinia sekä dopamiinihermosoluja. Toisaalta GDNF cKO hiirillä dopamiinipitoisuudet ja 
-solumäärät säilyivät muuttumattomia, jopa hyvin vanhoilla hiirillä, ja riippumatta GDNF:n 
poistamisen ajankohdasta. Molemmilla hiirikannoilla dopamiinin takaisinotto oli voimistunut, 
kun taas amfetamiinivasteet olivat vahvistuneet GDNFh hiirillä ja heikentyneet GDNF cKO 
hiirillä. GDNFh hiirillä dopamiinia myös vapautui enemmän, minkä lisäksi kohonnet GDNF-
pitoisuudet suojasivat niitä kemiallisesti aiheutetulta Parkinsonismilta. Kaiken kaikkiaan aivojen 
dopamiinihermosolut näyttivät olevan herkempiä GDNF:n määrän kohtuulliselle lisääntymiselle 
kuin sen täydelliselle puuttumiselle. Dopamiinihermosolut kykenevät siis ilmeisesti jollain 
tavalla kompensoimaan GDNF:n puuttumisen. Tämä osoittaa selvän puutteen hyvin yleisesti 
käytetyissä geeninpoistomenetelmissä.
Tuloksemme viittaavat siihen että endogeenisella GDNF:llä on selvä rooli aivojen 
dopamiinihermosolujen kehityksessä ja toiminnassa. Toisaalta tuloksemme myös osoittavat, 
ettei GDNF:ää välttämättä tarvita ylläpitämään niitä yksilön vanhetessa. Lisäksi endogeenisen 
GDNF:n kyky suojella eläimiä Parkinsonin tautimallissa ilman GDNF-annosteluun tavallisesti 
liittyviä sivuvaikutuksia merkitsee, että endogeenisen GDNF:n lisääminen saattaisi joskus 
tulevaisuudessa olla tehokas tapa hoitaa Parkinsonin tautia.
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11 INTRODUCTION
In the absence of external signals most cells quickly die through an active process of programmed 
cell death. In multicellular organisms this internal ‘death signal’ is normally counterbalanced 
by external survival and growth signals. Th ese signals not only keep the right cells alive but 
also regulate the size, shape, formation and function of diff erent tissues and organs. Our body 
synthesizes a large number of diff erent growth factors – small, secreted proteins – that deliver 
survival and growth signals for the cells that carry cognate receptors on their surface. Th e brain 
is no exception to this generality.
Neurotrophic factors compromise a superfamily of growth factors that regulate the life of 
neurons, being involved in almost every aspect of their lifecycle from development to death. 
Glial cell line-Derived Neurotrophic Factor (GDNF) is best known for its ability to support 
midbrain dopaminergic neurons (Lin et al., 1993), although it also regulates certain other 
neuronal populations and has critically important functions outside the nervous system, such as 
regulation of kidney and enteric nervous system development (Airaksinen and Saarma, 2002). 
Midbrain dopamine neurons regulate some very important aspects of our behavior including 
motivation, attention, associative learning, emotions, cognition and initiation of movements.
Parkinson’s disease is an example of a serious disease, where inadequate dopamine system 
function plays an important role. Due to its potent dopaminotrophic eff ects, GDNF has been 
extensively studied as a potential novel disease-modifying drug candidate for the dopaminergic 
neurodegeneration, which causes many of the classical motor symptoms of Parkinson’s disease. 
Th ese studies have taken intracranial ectopic GDNF application all the way into clinical trials 
with Parkinson’s disease patients with variable success and new clinical studies again ongoing 
(Olanow et al., 2015). While most attention has been directed to the ability of ectopic GDNF 
to recover and save damaged dopamine neurons, its eff ects on intact dopamine neurons has 
received less attention. Furthermore, the focus on the potential therapeutic aspects of ectopically 
applied GDNF protein has oft en blurred the fact that the exact role and functions of endogenous, 
physiological GDNF, especially in the adult brain, are still rather unknown. Th e main reason for 
this is that the complete removal of GDNF from the body via GDNF gene deletion causes death 
very soon aft er birth due to kidney agenesis and lack of enteric nervous system distal from the 
stomach (Pichel et al., 1996; Airaksinen and Saarma, 2002).
In the present study, we have used novel and innovative in vivo approaches to circumvent 
this problem in order to uncover the functions of endogenous GDNF in the brain and elsewhere 
in the body. Th is thesis provides new knowledge about the role of endogenous GDNF as a 
regulator of midbrain dopamine neurons.
Introduction
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2.1 The brain dopamine systems
Based on their pioneering work in the late 1950s, Arvid Carlsson and coworkers proposed that 
dopamine would also act as an independent neurotransmitter in the brain, instead of being a mere 
precursor for noradrenaline and adrenaline (Carlsson et al., 1957, 1958; Carlsson, 1959). Since 
that time, brain dopamine pathways have been subjects of intensive studies. Later discoveries 
that dopamine pathways regulate many important behaviors and associate to the pathogenesis of 
various diseases further fueled the scientifi c interest towards brain dopamine systems.
Dopamine pathways regulate motivated behavior through their role in reward signaling and 
thus have a central role in behavioral reinforcement and associative learning. Striatal dopamine 
signaling creates associations between a context and a meaningful outcome. Th is context can be 
either external, like a particular environmental cue, or internal, like a particular behavior or a set 
of behaviors. Th e resulting outcome can be either positive leading to reinforcement or negative 
leading to aversion. Repeated reinforcements of behavior lead to generation of an automatic 
motor program (a theoretical representation of planned movements) or a habit. During this 
process, the neuronal control of behavior shift s from ventral to dorsal striatum. If this habit 
formation is particularly strong due to repeated, strongly reinforcing stimuli the resulting 
behaviors may become compulsive, as happens in most addictions. Th ese neural mechanisms are 
reviewed more comprehensively by (Wise, 2004). 
In addition to learning and acquisition of motor programs, dopamine plays an important 
role in the selection and initiation of appropriate behavioral responses (decision-making), 
regulation of attention, emotions and working memory as well as moment-to-moment motor 
control and motor programming.
Th e signifi cance of brain dopamine systems is highlighted by the fact that the deterioration 
of their normal function is associated with various neurological and psychiatric disorders like 
Parkinson’s disease (PD), Huntington’s disease, depression, schizophrenia, ADHD, bipolar 
disorder, compulsive disorder as well as various addictions.
2.1.1 Midbrain dopamine neurons and their connecƟ vity
In the mammalian mesencephalon dopamine neuron cell bodies are located in substantia nigra 
pars compacta (SNpc), ventral tegmental area (VTA) and the retrorubral fi eld (RRF), which 
respectively correspond to the cell groups A9, A10 and A8 (Dahlström and Fuxe, 1964; Fuxe, 
1965). Th ese neurons send their long axons via the medial forebrain bundle to the cortical, 
limbic and striatal areas of the brain (Figure 2.1). Whereas in rodent neocortex dopaminergic 
innervation is limited to the frontal, cingulate and entorhinal cortex, in primates (like humans) 
the entire cortical mantel receives dopaminergic innervation (Berger et al., 1988, 1991; Gaspar et 
al., 1989; Meador-Woodruff  et al., 1996). Th e limbic areas innervated by the dopamine neurons 
in A10 are ventral striatum (including nucleus accumbens), amygdala, olfactory tubercle and 
septum. Th e dorsal sensorimotor compartment of striatum (or caudate-putamen) receives 
dopaminergic innervation almost exclusively from the SNpc A9 group of neurons that form the 
nigrostriatal pathway (Andén et al., 1964; Dahlström and Fuxe, 1964; Dahlström et al., 1964; 
Hokfelt and Ungerstedt, 1969; Ungerstedt, 1971). Similarly, the connections from RRF A8 and 
VTA A10 dopamine neurons to the limbic and cortical structures form the mesocorticolimbic 
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pathway that is oft en separated into mesolimbic and mesocortical tracts (Dahlström et al., 1964; 
Ungerstedt, 1971; Th ierry et al., 1973; Swanson, 1982; Björklund and Dunnett, 2007). Th ere 
are several molecular markers that are diff erently expressed by the A9 and A10 cell groups: A9 
neurons express aldehyde dehydrogenase 2 (Ahd2) and G protein-regulated inward rectifi er K+ 
channel subfamily-J member-6 (Girk2/KCNJ6), while A10 neurons predominantly express the 
calcium-binding proteins calbindin 1 and 2 (Calb1 and 2) and cholecystokinin (CCK) (Veenvliet 
et al., 2013). Further anatomical and functional diversity of midbrain dopamine systems is 
beginning to be defi ned as novel research tools allow characterization of new dopaminergic 
subpopulations within the SNpc and VTA (Reviewed by Roeper 2013). Th e mouse midbrain 
contains around 20,000-30,000 dopamine neurons, out of which ~50 % reside in the SNpc 
(Björklund and Dunnett, 2007). Th is thesis focuses mainly on SNpc dopamine neurons that 
form the nigrostriatal dopaminergic system.
A recent study revealed that SNpc dopamine neurons have extremely wide and dense axonal 
arborizations enabling a single neuron to cover up to 6 % of the total volume of rat striatum 
(Matsuda et al., 2009). Consequently, it was estimated that around 75,000 striatal neurons are 
directly infl uenced by a single dopamine neuron. While a single neostriatal neuron is estimated 
to be simultaneously under the infl uence of 95-194 dopaminergic neurons (Matsuda et al., 2009), 
this raises an obvious question of the implications for this exceptional degree of overlap and 
redundancy in the dopaminergic innervation. Th e authors speculated that the answer might be 
in an inherent lability of dopaminergic neurons that needs to be compensated by high safety 
margins. Th is overlap might also be necessary for learning or fi ne-tuning complex motor 
programs.
Figure 2.1. Dopaminergic forebrain projections from the ventral midbrain. Schematic presentation 
of the main dopaminergic projections from substantia nigra pars compacta (SNpc, A9), ventral 
tegmental area (VTA, A10) and the retrorubral fi eld (RRF, A8). Th ese neuronal groups send major 
axonal projections to dorsal striatum (dSTR) as well as nucleus accumbens (NAc) and prefrontal 
cortex (PFC). Th ese long dopaminergic projections are called nigrostriatal and mesocorticolimbic 
tracks, respectively.
SNpc
VTA RRFNAc
dSTR
PFC
4Dopaminergic neurons have an intrinsic pacemaker activity that allows them to continuously 
release low amounts of dopamine (Grace and Bunney, 1984). Synaptic inputs then modify this 
tonic fi ring pattern in response to internal and external stimuli causing either transient pauses or 
phasic bursts in activity (Bunney et al., 1973a, 1973b; Grace and Bunney, 1984; Lee and Tepper, 
2009; Tritsch and Sabatini, 2012). An elegant and comprehensive study mapped all the direct, 
monosynaptic inputs to the SNpc and VTA dopamine neurons in mouse brain (Watabe-Uchida et 
al., 2012). Th e study largely confi rmed and further refi ned the known rich connectivity from the 
basal ganglia and the signifi cant connectivity from many other brain structures to the dopamine 
neurons. Perhaps most interestingly, the monosynaptic inputs solely to the SNpc neurons came 
from somatosensory and motor cortices as well as from subthalamic nucleus (STN) and dorsal 
striatum, while the VTA neurons received exclusive inputs from hypothalamus, lateral orbital 
cortex and ventral striatum (Watabe-Uchida et al., 2012).
Importantly, dopamine is not only released from the axonal terminals, but also from the 
somatodendritic areas of the SNpc (and VTA) and from the dendrites that extend throughout 
large parts of substantia nigra pars reticulata (SNpr) (Björklund and Lindvall, 1975; Robertson 
and Robertson, 1989; Robertson et al., 1991; Cragg et al., 1997; Rice et al., 1997; Hoff man and 
Gerhardt, 1999). As SNpr functions as a basal ganglia output nucleus (reviewed later below) the 
direct dopaminergic regulation of motor behaviors also takes place via somatodendritic release 
(Rice et al., 2015). In addition, the dopaminergic dendrites extending to SNpr receive more 
GABAergic inhibitory innervation than the dendrites in the SNpc region which contributes 
to the specifi c fi ring patterns of diff erent SNpc neurons (Henny et al., 2012). Somatodendritic 
dopamine also regulates the fi ring activity in neighboring dopamine neurons via inhibitory 
dopamine D2 autoreceptors (Rice et al., 2015). Th is mechanism shapes the patterns of release in 
the axonal terminals (Rice et al., 2015). 
2.1.2 Midbrain dopamine neuron development
Th e full complement of midbrain dopamine neurons takes place in multiple phases that include 
specifi cation of the neuronal fi eld where the dopamine cells will form, cell diff erentiation and 
migration of the immature dopamine neuron precursors to their specifi c positions, axonal 
outgrowth and connectivity, selective programmed cell death, and fi nally maintenance of the 
mature dopamine neurons (Smidt and Burbach, 2007). Further importance of understanding 
dopamine neuron development comes from the fact that many of the developmental factors are 
also important for the function, plasticity and maintenance of these neurons during adulthood 
and aging.
Dopamine neuron neurogenesis takes place approximately between embryonic day (E) 
9.5 and E14.5 in the mouse embryo (Luo and Huang, 2015). Th e main external determinants 
in the initial patterning process are fi broblast growth factor 8 (FGF8) produced by the isthmus 
and the morphogen sonic hedgehog (Shh) initially secreted by the notochord. Intersection of 
these two signals defi nes the neuronal fi eld within the ventricular zone where the midbrain 
dopamine neurons are born, but the process also requires transforming growth factor β (TGFβ) 
and WNT (mainly Wnt1 and Wnt5a) signaling (Smidt and Burbach, 2007; Arenas et al., 2015; 
Luo and Huang, 2015). Aft er the initial patterning, the expression of several cell type-specifi c 
transcription factors that include Nurr1, Pitx3, Engrailed-1/2 (En1/2), Otx2, Foxa1/2, Ngn2, 
Mash1, Msx1, LXRα/β and Lmx1a/b are needed for the progenitor cells to fi nally attain the 
proper dopaminergic identity (Smidt and Burbach, 2007; Alavian et al., 2008; Arenas et al., 2015). 
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be seen as part of the diff erentiation program and they indeed occur simultaneously (Arenas 
et al., 2015). Th is migration is regulated by several factors, most important being C-X-C motif 
chemokine 12 (CXCL12) and its receptor C-X-C motif chemokine receptor type 4 (CXCR4) that 
control radial migration and RELN (reelin) signaling that controls tangential migration (Arenas 
et al., 2015).
Out of the transcription factors mentioned above the ‘late’ transcription factors Nurr1, Pitx3 
and En1/2 control the acquisition of mature dopaminergic phenotype and remain expressed 
until adulthood. Th ey regulate each other’s expression as well as the expression of many genes 
that defi ne the mature dopaminergic neuron including TH, VMAT2, DAT, AADC, D2 receptor 
and GDNF receptor Ret (Arenas et al., 2015). Interestingly, Nurr1 seems to be required for the 
proper development of all midbrain dopamine neurons, while Pitx3 seems to be more important 
for SNpc cells and En1 for VTA neurons (Veenvliet et al., 2013). It appears that the crosstalk 
between these two factors strongly infl uences the specifi cation of the two midbrain dopamine 
neuron subsets, SNpc and VTA neurons, during development (Veenvliet et al., 2013). Other key 
regulators of this diff erentiation process appear to be Otx2-Wnt1-Lmx1a/b and Shh-Foxa1/2 
pathways, specifying VTA and SNpc neurons respectively (Arenas et al., 2015).
Once established, the diff erent midbrain dopamine neuron systems need to be maintained 
throughout the entire adult life. Th is is achieved by diff erential expression of transcription factors 
and other key regulators, like neurotrophic factors, which will be summarized in a later section. 
For example, in addition to their crucial roles in terminal diff erentiation, Nurr1, Pitx3, En1/2 
and Otx2 also regulate dopamine neuron maintenance and survival until the end of embryonic 
development and throughout the postnatal life (Alavian et al., 2008; Di Salvio et al., 2010; Arenas 
et al., 2015).
Striatum and cortical areas receive dopaminergic innervation by mid-to-late gestation, 
signifi cantly earlier in primates than in rodents (Money and Stanwood, 2013). In rats this 
begins at E14 (Specht et al., 1981) and in humans as early as 6-7th gestational week (Verney et 
al., 1991; Zecevic and Verney, 1995). Th is coincides with striatal and cortical neurogenesis and 
diff erentiation and dopamine critically modulates the developmental processes in these regions 
(Money and Stanwood, 2013). During development, most neuronal populations go through a 
natural, programmed and regulated cell death process that can reduce their initial numbers by 
over half (Cowan et al., 1984). As an apparent part of the normal maturation process apoptotic 
cell death also takes place in the SNpc dopamine neurons of rats (Janec and Burke, 1993; Oo 
and Burke, 1997) and mice (Jackson-Lewis et al., 2000). In mice the developmental apoptosis 
of dopamine neurons peaks at postnatal days (P) 2 and P14 and is largely over by P30 (Jackson-
Lewis et al., 2000). Th e process is dependent on the target structure, the striatum, and most 
likely regulates adequate and eff ective target innervation (Jackson-Lewis et al., 2000). Hence, 
dopamine neuron development and maturation continue postnatally. Th is period (especially 
adolescence) is suggested to be associated with particular behaviors (impulsivity, sensation 
seeking), vulnerabilities and onset of many neuropsychiatric diseases (Money and Stanwood, 
2013).
2.1.3 Dopamine lifecycle
Dopamine challenges the classical view of neurotransmitters as short-lived molecules that relay 
quick and precise point-to-point signals over synaptic cleft s and are then quickly degraded 
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lifetime 10-100 ms) and diff use signal that spreads extensively in the extracellular space reaching 
receptors far away from the release site (up to 7 μm) (Ungerstedt et al., 1969; Agnati et al., 1995; 
Rice and Cragg, 2008; Fuxe et al., 2015). Dopamine signal is not designed to be precise. In fact 
most axonal dopamine release terminals completely lack specialized post synaptic structures 
(Wilson et al., 1977; Descarries et al., 1996; Rice et al., 2011; Taber and Hurley, 2014). A recent 
electron microscopy study estimated synaptic incident of dopamine terminals to be around 5 % 
in the mouse striatum (Bérubé-Carrière et al., 2012). It is estimated that aft er a quantal release 
dopamine can encounter ~300-2500 synapses (depending on the quantal size) in the striatum 
until its concentration falls too low to activate high affi  nity receptors (Rice and Cragg, 2008). 
Th is sort of extracellular fl uid-mediated ‘volume transmission’ is typical for all the monoamine 
transmitters and oft en changes the activity state of larger brain areas and can result in changes 
in mood, attention or alertness (Taber and Hurley, 2014; Fuxe et al., 2015). Interestingly, there is 
convincing new evidence that dopamine neurons can co-release γ-aminobutyric acid (GABA) 
(Tritsch et al., 2012, 2014, 2016; Stamatakis et al., 2013) and glutamate (Yamaguchi et al., 2011; 
Broussard, 2012; Li et al., 2013; Zhang et al., 2015), but the exact signifi cance of this phenomenon 
is unclear. 
Although dopamine neuron fi ring is the main determinant of striatal dopamine release, it 
alone fails to provide suffi  cient local specifi city to the dopamine signal, as a single dopamine 
neuron covers up to 6 % of total striatal volume with its axonal tree (Matsuda et al., 2009). 
Th e high level of temporal and spatial regulation observed in the striatum results from diverse 
local regulatory and gating mechanisms for dopamine release. Th us, striatal dopamine release 
is driven and regulated at two independent levels: distantly, through SNpc/VTA fi ring activity, 
and locally at the striatal level through reuptake, autoreceptor- and heteroreceptor-dependent 
modulation, as well as termino-terminal and local network (striatal interneurons) control (Rice 
et al., 2011; Cachope and Cheer, 2014; Sulzer et al., 2016)A.
In most brain areas the dopamine signal is not terminated by degradation or rapid 
uptake, but primarily by passive diff usion and only secondarily by active reuptake back into 
the dopaminergic neurons by a specifi c dopamine transporter (DAT) (Cragg and Rice, 2004; 
Rice and Cragg, 2008). Th is is evidenced by small eff ects of uptake inhibition on the “eff ective 
radius” (7 μm vs. 8.2 μm), where dopamine concentration aft er quantal release remains high 
enough to activate high affi  nity dopamine (D2) receptors (Cragg and Rice, 2004; Rice and Cragg, 
2008). However, the small diff erence in eff ective radius still means that the released dopamine 
will activate 40 % lower number of D2 receptors within its sphere of infl uence (Rice and Cragg, 
2008).  Uptake has an even smaller impact on the eff ective radius or the sphere of infl uence of 
the low affi  nity dopamine (D1) receptors (Rice and Cragg, 2008). Importantly, DAT has a much 
greater infl uence on larger dopamine transients that result from release of multiple vesicles due 
to burst fi ring or summation of multiple release sites (Floresco et al., 2003; Rice and Cragg, 2008). 
Finally, the main role of striatal DAT is to limit dopamine lifetime aft er release, which directly 
infl uences dopamine transmission (Cragg and Rice, 2004; Rice and Cragg, 2008). In mice lacking 
DAT, dopamine persists 100 times longer in the extracellular space and various compensatory 
changes ensue (Giros et al., 1996; Jones et al., 1998; Jaber et al., 1999). Th us, the key role of DAT 
is not in the termination of normal dopamine signal, but in dopamine clearance and recycling 
that maintain homeostasis and in the control of larger dopamine transients. In comparison to 
the glutamate transporter that exists primarily on non-glutamatergic cells, like astroglial cells 
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neurons (Ciliax et al., 1995; Nirenberg et al., 1996, 1997; Hersch et al., 1997) and its uptake rate 
is around ten times slower (Wadiche et al., 1995; Povlock and Schenk, 1997; Prasad and Amara, 
2001). DAT expression is also primarily extrasynaptic and the dopamine uptake sites are rather 
evenly distributed along the surface of dopaminergic fi bers (Nirenberg et al., 1996; Pickel et al., 
1996; Hersch et al., 1997). Due to its slow kinetics and limited expression DAT cannot compete 
with the quick escape of dopamine from the site of release by diff usion (Cragg and Rice, 2004; 
Rice and Cragg, 2008). Th is allows dopamine to reach receptors far away from the site of release. 
Several types of proteins including kinases, receptors and scaff olding proteins interact with DAT, 
modulating either its catalytic activity or cellular membrane traffi  cking (Eriksen et al., 2010).
An important level of control for dopamine signaling comes from its highly regulated 
biosynthetic pathway, where amino acid tyrosine is converted to L-3,4-dihydroxyphenylalanine 
(L-DOPA) and further to dopamine. Cytosolic enzyme tyrosine hydroxylase (TH) catalyzes 
the fi rst (Nagatsu et al., 1964) and rate-limiting (Levitt et al., 1965) step of this pathway, while 
aromatic L-amino acid decarboxylase (AADC) catalyzes the second. As an indication of its 
importance, the amount and enzymatic activity of TH are tightly regulated at transcriptional, 
translational and post translational levels (Tekin et al., 2014). Th e most dynamic regulation on TH 
activity comes from the direct feedback inhibition by dopamine as well as from phosphorylation 
and dephosphorylation of its three serine residues (Ser19, 31 and 40) (Tekin et al., 2014), which 
regulate synthesis. 
As all catecholamines (dopamine, noradrenaline and adrenaline) react with oxygen at 
neutral pH to generate toxic derivatives, they are mostly synthetized on demand and stored 
in acidic synaptic vesicles (Graham et al., 1978; Hastings and Zigmond, 1994; Hastings et al., 
1996; Tekin et al., 2014). Th erefore any uptaken or newly synthetized dopamine is subsequently 
packed into storage vesicles by the vesicular monoamine transporter 2 (VMAT2) or alternatively 
metabolized by enzymes monoamine oxidase (MAO) and aldehyde dehydrogenase to 
3,4-dihydroxyphenylacetic acid (DOPAC)  (Eisenhofer et al., 2004). DOPAC is then further 
metabolized by catechol-O-methyl-transferase (COMT) into homovanilic acid (HVA), which 
is ultimately secreted in urine (Elchisak et al., 1982). Contrary to the common view, most 
of the dopamine turnover and metabolism takes place within the dopaminergic cells due 
to the constitutive passive leakage from the storage vesicles to the surrounding cytoplasm 
independently of exocytotic release (Floor et al., 1995; Eisenhofer et al., 2004). Th is leakage is 
mostly balanced by active, energy-consuming transport back into the vesicles and only a small 
fraction (~10 %) of dopamine escapes vesicular sequestration by VMAT2. However, this fraction 
represents a major source of dopamine metabolites (Eisenhofer et al., 2004). VMAT2 activity 
therefore strongly aff ects dopamine storage, as is also indicated by VMAT2 heterozygous mice 
with increased tissue dopamine levels (Takahashi et al., 1997). VMAT2 also protects neurons 
from the cytosolic toxicity of dopamine and other catecholamines (Eiden and Weihe, 2011). 
High dopamine content in the nigrostriatal dopamine system may predispose these neurons to 
disturbances as it results in particularly high rates of vesicular leakage and energy consuming 
sequestration back into the vesicles (Eisenhofer et al., 2004).
Review of the Literature
82.1.4 Dopamine receptors and modulatory eﬀ ects
Th e dopamine signal is received by dopamine receptors, which belong to the family of 
metabotropic G-protein coupled receptors (GPCRs). Dopamine receptors are primarily, but 
not exclusively, located outside synapses and oft en some distance away from the dopamine 
release sites (Sesack et al., 1994; Hersch et al., 1995; Yung et al., 1995; Khan et al., 1998). Th e fi ve 
dopamine receptors are divided into two subclasses based on their structural, pharmacological 
and signaling properties: D1-like receptors (D1 and D5) and D2-like receptors (D2, D3 and D4). 
D1 and D2 receptors are the most abundant subtypes in the brain, D1 displaying the widest 
distribution and highest expression (Jaber et al., 1997). Th e expression of the other subtypes 
(D3, D4 and D5) is substantially more restricted and less dense (Jaber et al., 1997). Th e affi  nity 
of D2-like receptors for dopamine is 10 to 100 fold higher than that of D1-like receptors with 
values of ~10 nM for D2 versus ~1 μM for D1 (Richfi eld et al., 1989; Beaulieu and Gainetdinov, 
2011; Sulzer et al., 2016). Hence, the basal extracellular levels of dopamine (10-20 nM) would 
only activate D2 receptors. D1 receptors are positively coupled to adenylyl cyclase (Brown 
and Makman, 1972; Kebabian et al., 1972; Kebabian and Calne, 1979), leading to production 
of cyclic adenosine monophosphate (cAMP) and activation of protein kinase A (PKA), which 
phosphorylates various intracellular targets. By contrast, D2-like receptors are negatively coupled 
to adenylyl cyclase (Giannattasio et al., 1981; Onali et al., 1983; McDonald et al., 1984; Enjalbert 
et al., 1986, 1990), and activate protein phosphatases that directly counter the eff ects of PKA. 
Th us, these two signaling pathways have primarily opposite cellular eff ects.
Th e eff ects and mechanisms of dopamine signaling are highly complex and not completely 
understood. Dopamine downstream signaling includes a variety of molecules such as 
phosphatases, kinases, transcription factors, ion channels and receptors. Furthermore, actions of 
dopamine vary greatly depending on target cell types, their activity states, strength and duration 
of receptor stimulation as well as other neuromodulators tapping into the same pathways (Tritsch 
and Sabatini, 2012).
 Instead of directly exciting or inhibiting a target cell, dopamine usually modulates 
neurotransmission through other synapses (Figure 2.2). Th is neuromodulation infl uences the 
excitability of pre- and postsynaptic membranes, the amount of neurotransmitter released as 
well as receptor traffi  cking and sensitivity (Tritsch and Sabatini, 2012). Th us, dopamine either 
facilitates or hampers the information fl ow in neural circuits. Th is eff ect can be either transient 
or long lasting. Dopamine’s eff ects can also be indirect. For example, (typically negative) 
modulation of transmitter release probability happens both directly via presynaptic, inhibitory 
D2 receptors and indirectly via postsynaptic retrograde mediators like hydrogen peroxide 
(H2O2), nitric oxide (NO) or endocannabinoids. D2 receptors are also located on dopaminergic 
terminals as autoreceptors providing negative feedback inhibition of dopamine synthesis and 
release (Ford, 2014). Figure 2.2 summarizes dopamine’s potential modulatory eff ects on synaptic 
transmission. 
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Figure 2.2. Dopaminergic modulation of synaptic transmission. Dopamine neurons do not 
usually form classical synapses with target cells, but modulate neurotransmission in other synapses. 
Dopamine’s eff ects on presynaptic (1), postsynaptic (2) and dopaminergic (3) terminals are displayed. 
Dopamine transporters (DAT) are unable to prevent dopamine (DA) from escaping the site of release 
and activating receptors far away. Dopamine can modulate membrane excitability and transmitter 
release by its eff ects on ion channels (1-3) and vesicular release mechanisms (1, 3). Th ese eff ects can 
be direct (1, 3) or indirect involving retrograde mediators from postsynaptic cells, like nitric oxide 
(NO) (2). Postsynaptic dopamine receptors infl uence signal detection by regulating receptor function 
and traffi  cking (2). Dopamine also mediates its own synthesis by tyrosine hydroxylase (TH) and 
release through D2 autoreceptors (3). Glut, glutamate. Figure inspired by (Tritsch and Sabatini, 2012) 
and (Rice and Cragg, 2008).
2.1.5 Dopaminergic modulaƟ on of basal ganglia output
Basal ganglia are a highly conserved chain of subcortical nuclei that play a key role in action 
selection and movement control. Th eir function is to select which one of the various competing 
neural input systems will receive access to motor mechanisms capable of driving behavior 
(Redgrave et al., 2011). Movements occur during pauses in the tonic inhibitory activity in the 
basal ganglia interface as specifi c voluntary motor programs are facilitated and the potentially 
interfering surrounding patterns are inhibited (Mink, 2003; Cisek and Kalaska, 2010). Two 
parallel pathways within the basal ganglia achieve this movement specifi city together: Th e direct 
pathway facilitates the wanted movement patterns, while the indirect pathway suppresses the 
surrounding unwanted patterns (DeLong and Wichmann, 2007). Figure 2.3 depicts the basic 
organization of basal ganglia.
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Figure 2.3. Th e basic organization of the basal ganglia circuits. Th e striatum receives excitatory 
glutamatergic input (wide green arrows) from cortex and thalamus. Th e inhibitory basal ganglia 
output (wide red arrows) projects from the internal segment of the globus pallidus (GPi) and 
substantia nigra pars reticulata (SNr) to thalamus, superior colliculus and pedunculopontine nucleus 
(PPN). Th e direct pathway from D1 receptor expressing spiny projection neurons (SPNs; thin red 
arrows) projects directly to the output nuclei. Th e indirect pathway from D2 receptor expressing SPNs 
(thin blue arrows) projects only to the external segment of the globus pallidus (GPe), which together 
with the subthalamic nucleus (STN) connects the signal to the output nuclei. Unlike the rest of the 
basal ganglia nuclei, projections sent by STN are glutamatergic (thin green arrows). Figure adapted 
from (Gerfen and Surmeier, 2011).
Basal ganglia include the striatum, internal and external segment of globus pallidus (GPi and 
GPe), subthalamic nucleus (STN) and substantia nigra pars reticulata (SNpr). GPi and SNpr are 
the two basal ganglia output nuclei: GPi controls axial and limb movements and SNpr controls 
head and eye movements (Gerfen and Surmeier, 2011). Th e output nuclei project to thalamus, 
superior colliculus, and pedunculopontine nucleus (PPN) (Figure 2.3) (Cisek and Kalaska, 2010; 
Gerfen and Surmeier, 2011). Striatum, which comprises dorsal striatum (or caudate putamen) 
and ventral striatum, is the largest of the basal ganglia nuclei. It is the principal integrator for 
basal ganglia information as it receives excitatory glutamatergic input from the cortical areas, 
limbic structures and thalamus (Sesack and Grace, 2010; Gerfen and Surmeier, 2011; Stuber et al., 
2012). Striatum is believed to perform  computation on sensorimotor, cognitive and emotional/
motivational information to facilitate the selection of appropriate action (Cisek and Kalaska, 
2010; Redgrave et al., 2011). Striatum also has the richest dopaminergic innervation in the entire 
central nervous system and dopamine can potentially modulate any information arriving there. 
Striatum is almost fully populated by two types of GABAergic spiny projection neurons 
(SPNs; also called medium spiny neurons, MSN) that are nearly equal in numbers and constitute 
over 90 % of striatal cells (Gerfen and Surmeier, 2011). Th ey form two parallel pathways from 
striatum to the two basal ganglia output nuclei: GPi and SNpr. Th e fi rst group of GABAergic 
neurons express D1 receptors, substance P and dynorphin and projects directly to the output 
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nuclei (the striatonigral or so-called direct pathway; dSPNs) together with a minor axon 
collaterals to the GPe. Th e second GABAergic group express D2 receptors and encephalin and 
projects exclusively to the GPe. GPe GABAergic neurons then project to the STN and to the 
output nuclei. Finally, STN glutamatergic neurons also project to the output nuclei forming a 
parallel pathway. Th is second pathway is called indirect pathway (iSPNs) (Gerfen and Surmeier, 
2011). Figure 2.3 displays these complex striatal projections.
If there were not any inherent activity in the basal ganglia circuit, the inhibitory signal from 
the SPNs would simply silence the circuit further. However, as all the neurons in GPe, STN, 
GPi and SNpr are generating action potentials on their own (autonomous pacemakers), the 
GABAergic activity of SPNs is able to modulate the basal ganglia circuit output bidirectionally 
(increasing or decreasing) (Gerfen and Surmeier, 2011). Th e indirect pathway inhibits movement 
through the basal ganglia circuit, as it increases the inhibitory tone at the output interface. Th e 
direct pathway infl uence is facilitative as it causes a transient pause in the inhibitory tone, which 
allows specifi c movements to happen. As dSPNs express the facilitatory D1 receptors and iSPNs 
express the inhibitory D2 receptors, a phasic dopamine signal in the striatum has an opposite 
eff ect on the activity of these neurons. Hence, dopamine produces a transient motor signal by 
enhancing the direct pathway responsiveness and decreasing the opposing indirect pathway. Th is 
suggests a role for dopamine in motor signal gating.
Th e above model for dopaminergic regulation of striatal output is still relatively simple and 
straightforward. However, the actual situation is more complex. Next to the SPNs which make 
up the majority of the striatal neurons, the local striatal interneurons that also express dopamine 
receptors are important regulators of striatal circuits (Gerfen and Surmeier, 2011). Th ese neurons 
constitute around 5 % of all neurons in the rodent striatum (Tepper et al., 2010). Currently the 
behavioral relevance of the local striatal interneurons remains very poorly understood, although 
they strongly infl uence basal ganglia output. Th ere are three well characterized subtypes of 
GABAergic interneurons out of which parvalbumin expressing (PV+) and  somatostatin, nitric 
oxide synthase and neuropeptide Y expressing (SOM/NOS/NPY+) neurons are described briefl y 
below. For a comprehensive review see (Tepper et al., 2010). Cortical pyramidal neurons send 
glutamatergic projections directly to fast-spiking PV+ GABAergic interneurons in the striatum. 
Th e PV+ interneurons convey this activity to both direct and indirect SPNs eliciting inhibition 
(Tepper et al., 2010). Th is powerful feedforward inhibition is believed to contribute to action 
selection as it suppresses SPN activity in circuits associated with unwanted actions. In addition, 
PV+ interneurons receive inhibitory feedback projections from GPe neurons. Similarly, SOM/
NOS/NPY+ GABAergic interneurons also form a similar corticostriatal feedforward circuit as 
PV+ interneurons, but this system is less well studied. Th eir ability to produce NO is believed to 
mediate important biochemical cross-talk between the striatal neurons (Calabresi et al., 2014). 
In addition to the GABAergic interneurons, there is also one population of cholinergic 
interneurons in the striatum. Quite similar to the GABAergic interneurons, another major 
glutamatergic projection to the striatum comes from thalamus and connects to SPNs as well as the 
cholinergic interneurons. Th e cholinergic interneurons create another feedforward connection to 
SPNs that is biphasic. Th e fi rst phase is inhibitory while the slower second one is excitatory and 
together they are thought to signal responses to salient stimuli. As the cholinergic interneurons 
carry dopamine receptors, dopamine is able to modulate this system as well. Moreover, in the 
striatum dopaminergic and cholinergic systems dynamically and reciprocally regulate each 
other in multiple diff erent ways that are not completely resolved (Tritsch and Sabatini, 2012). A 
recent study showed how cholinergic interneurons can directly trigger dopamine release from 
Review of the Literature
12
presynaptic terminals, bypassing dopamine neuron fi ring activity (Th relfell et al., 2012). Finally, 
the cholinergic interneurons have also been hypothesized to mediate the synaptic cross-talk 
between the two classes of SPNs (Calabresi et al., 2014). It was recently shown that striatal PV+ 
interneurons, although tightly interconnected with each other and SPNs, do not synapse with 
the cholinergic interneurons and only very weakly synapse with SOM/NOS/NPY+ interneurons 
(Szydlowski et al., 2013). Th is suggests independent roles for the diff erent striatal interneuron 
populations in regulation of striatal output.
Another mechanism that complicates the classical model of dopamine regulation of basal 
ganglia function is related to learning. In addition to modulating the ongoing activity in the basal 
ganglia network (motor coordination), dopamine also regulates long-term changes in synaptic 
strength (Gerfen and Surmeier, 2011). Th ese synaptic plasticity mechanisms include long-term 
depression (LTD) as well as long-term potentiation (LTP) and they are believed to underlie 
various aspects of learning and habit formation. LTD and LTP indicate persistent weakening or 
strengthening in synaptic transmission strength, respectively, based on recent activity patterns. 
In the striatum they provide a mechanism for the dopamine signal’s ability to direct behavior 
towards rewarding cues and away from the aversive cues (Gerfen and Surmeier, 2011). Hence, 
a key role for dopaminergic basal ganglia regulation is the reinforcement of behaviors that have 
previously led to positive outcomes.
In conclusion, basal ganglia constitute a complex system of multiple interacting pathways. 
Dopamine modulates basal ganglia output through the prominent striatal input both directly 
and indirectly by modulating SPN activity and the various striatal interneurons. Importantly, 
dopamine modulates both immediate and long-term responsiveness of the system. Furthermore, 
the interneurons and other inputs also infl uence the striatal dopamine release as described above.
2.1.6 Parkinson’s disease and dopaminergic degeneraƟ on
Indian medical literature described a neurological disease with slowness and akinesia (later 
known as Kampavata) as early as 600 BC and the condition was treated with powdered seeds 
of atmagupta (Mucuna pruriens) (Ovallath and Deepa, 2013). Th ese seeds have been shown 
to contain 4-6 % of levodopa (Daxenbichler et al., 1972). In Western medical literature, James 
Parkinson provided the fi rst coherent picture of PD symptoms in “An essay on the Shaking 
Palsy” in 1817 (Parkinson, 2002). However, it took nearly 150 years more before the dopamine-
defi ciency was associated to PD and the eff ectiveness of levodopa was demonstrated and brought 
into clinical practice (Degkwitz et al., 1960; Ehringer and Hornykiewich, 1960; Birkmayer and 
Hornykiewich, 1961; Cotzias, 1968).
PD is a chronically progressive neurodegenerative disease with strongly age-related 
prevalence. Th e classical motor symptoms of PD, including rigidity, bradykinesia and resting 
tremors, mostly result from the gradual degeneration and death of SNpc dopaminergic 
neurons and the consequent loss of dopamine in the dorsal striatum (Lees et al., 2009). Along 
with dopamine, various other neuronal systems also progressively degenerate in PD causing 
the diff erent ‘non-motor’ symptoms of the disease including dementia, depression, sleep 
abnormalities, loss of smell and autonomic failure that manifests as constipation, incontinence 
and orthostatic hypotension (Meissner et al., 2011). Th e shared hallmark of the disease is the 
appearance of intracellular Lewy body inclusions that contain aggregated proteins, the most 
abundant being α-synuclein that normally resides in the nerve terminals (Goedert et al., 
2013). Braak and coworkers originally identifi ed that in sporadic PD the spread of brain Lewy 
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body pathology typically follows a specifi c ascending pattern from the brain stem towards the 
cortical areas (Braak et al., 2003). Few years later they extended their hypothesis with evidence 
suggesting that the Lewy pathology spread may transfer from the enteric nervous system (ENS) 
to the CNS via vagus nerve (Braak et al., 2006). Indeed, the newest evidence supports the view 
that Lewy pathology may transmit via neuronal synapses from ENS through the vagus nerve to 
and from the olfactory bulb to the SN and further areas of the brain (reviewed by Klingelhoefer 
and Reichmann, 2015). Remarkably, the proposed initiation of PD pathology in the olfactory 
and gastrointestinal systems, the body’s gateways to the environment, suggests high importance 
of environmental factors in PD pathogenesis.
Generally, the classical motor symptoms, and the concurrent diagnosis, of the disease appear 
when about 30 % of SNpc dopamine neurons and 50-60 % of striatal dopamine are lost (Burke 
and Malley, 2013). Th is suggests that the earliest PD pathology targets the enormous axonal tree 
of the dopamine neurons and the degeneration takes place through a “dying-back” axonopathy 
(Burke and Malley, 2013). Th is is further supported by the appearance of α-synuclein-positive 
aggregates in neurites prior to nerve cell bodies (Kanazawa et al., 2012). However, the dying-
back theory also proposes that there is a clear window of opportunity to save and restore the 
degenerating axons in order to stop disease progression and alleviate the symptoms. Th e current 
therapies are entirely symptomatic aiming for replacement of striatal dopamine defi ciency with 
the dopamine precursor levodopa (L-dopa), MAO-B and COMT inhibitors as well as with 
dopamine receptor agonists (Meissner et al., 2011). Th e problems include limited effi  ciency, 
motor state fl uctuations, adverse side eff ects and inability of the therapies to slow down or 
reverse the neurodegenerative processes underlying the disease (Meissner et al., 2011). Due 
to this situation, there is a great demand for novel disease-modifying treatments that could 
aff ect the disease progression. Th e specifi c mutations in rare familiar PD cases have directed 
the current research focus towards pathological alterations in axonal transport, mitochondrial 
function, energy metabolism and oxidative stress, as well as protein degradation, misfolding, and 
aggregation (Meissner et al., 2011).
None of the current animal models of PD fully recapitulates the human condition, especially 
the progressive and widespread Lewy body pathology, and PD appears to be a syndrome that 
specifi cally aff ects man. Neurotoxin-based models of dopaminergic degeneration (Parkinsonism) 
are the most widely used and they relatively well reproduce the classical motor symptoms 
of PD. Neurotoxicity of 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) is based on a combination of oxidative stress and mitochondrial 
respiratory dysfunction, but in both cases degeneration is rapid and there is typically no Lewy-
body pathology (Duty and Jenner, 2011). Furthermore, as they are both specifi cally taken up 
to dopaminergic cells by DAT (Duty and Jenner, 2011), any alterations in DAT function aff ects 
their toxicity, which can be a confounding factor in some genetically modifi ed animals. Systemic 
MPTP does not work in rats, but is particularly eff ective in primates and appears to produce 
some relevant non-motor symptoms as well (Duty and Jenner, 2011). Rotenone is similar, but less 
specifi c and a much debated neurotoxin with variable eff ects (Duty and Jenner, 2011). However, 
its chronic, gastric administration might carry some relevance to human PD pathogenesis 
(Klingelhoefer and Reichmann, 2015). Proteasome inhibitors like lactacystin and epoximycin 
directly inhibit cellular protein degradation to induce aggregation and cell death, which carries 
some clear validity to PD pathogenesis (Duty and Jenner, 2011). Various transgenic mouse 
models have been created based on the mutations found in rare familiar PD cases, including 
various α-synuclein mutant mice. However, these animals do not appear to display proper 
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loss of nigrostriatal neurons (Duty and Jenner, 2011; Meissner et al., 2011). Adeno-associated 
viral (AAV) vector-delivered α-synuclein has been reported to produce prominent dopamine 
neuron loss in rats (Kirik et al., 2002; Decressac et al., 2012b). However, this model has been 
diffi  cult to replicate by other groups (personal communication with docent Mikko Airavaara 
and others). More recently, a transgenic α-synuclein overexpression mouse line created using 
bacterial artifi cial chromosome was reported to display age-dependent dopamine neuron loss 
(Janezic et al., 2013). It remains to be seen how accurately this mouse line replicates human PD 
pathology.  In conclusion, major progress in PD treatment will probably require development of 
better animal models that would be more relevant to the human condition.
2.2 Neurotrophic factors
Compared to most other cell types in the body, neurons exhibit a rather unique step in their 
development process: massive programmed cell death, which reduces 20-80 % of the initial 
numbers within a neuronal population (Oppenheim, 1991). Th is usually occurs relatively 
late in the neuronal maturation process following the phenotypic expression of their specifi c 
characteristics, especially the projection of axons to the target tissue (Oppenheim, 1991).
According to the classical neurotrophic factor hypothesis, young neurons compete for 
trophic factors that are released from the target in limited amounts (Hamburger and Levi-
Montalcini, 1949). Th ose neurons that manage to connect adequately with the target receive 
enough trophic support to survive, while others die by programmed cell death. Th e vital 
importance of target-derived neurotrophic support is well established for most peripheral 
neurons. However, in the CNS the situation appears to be more complex as neurotrophic factors 
can also be secreted by neighboring cells or a cell can produce trophic factors for itself (autocrine 
loop) (Landreth, 1999; Cerchia, 2006). Even though the fi rst target-derived neurotrophic 
factor, nerve growth factor (NGF), was originally identifi ed and later purifi ed according to 
this survival function (Hamburger and Levi-Montalcini, 1949), neurotrophic factors have 
many other functions as well. Th ey stimulate and guide axonal growth and synapse formation, 
support neuronal phenotype and functions, protect the neurons from degeneration and regulate 
neuroplasticity. Additionally, most neurotrophic factors also have important functions outside 
the nervous system. Structurally neurotrophic factors are small, oft en glycosylated, polypeptides 
that are secreted into the extracellular space where they can diff use and bind to their specifi c 
receptors. Neurotrophic factor receptors are oft en receptor tyrosine kinases (RTKs) that have an 
extracellular ligand binding domain, span the cell membrane once and have the kinase domain 
inside the cell. Aft er receptor binding, neurotrophic factors can be retro- or anterogradely 
transported over long distances (Altar and DiStefano, 1998; Reynolds et al., 2000). Due to their 
potent trophic eff ects, neurotrophic factors represent attractive drug development targets to 
support neuronal survival and function.
Four major classes comprise the family of neurotrophic factors: (i) Neurotrophins include 
NGF, brain-derived neurotrophic factor (BDNF), neuorotrophin-3 (NT-3) and -4 (NT-4); (ii) the 
GDNF family of ligands (GFLs); (iii) neurotrophic cytokines (neurokines); and (iv) the newest 
family of  cerebral dopamine neurotrophic factor (CDNF) and mesencephalic astrocyte-derived 
neurotrophic factor (MANF).
Review of the Literature
15
2.3 GDNF family of neurotrophic factors
GDNF family of neurotrophic factors consists of four closely related members: (i) GDNF, (ii) 
Neurturin (NRTN), (iii) Artemin (ARTN) and (iv) Persephin (PSPN). GDNF was originally 
purifi ed on the basis of its ability to support the survival of embryonic midbrain dopamine 
neurons (Lin et al., 1993) and NRTN by its ability to support sympathetic neurons (Kotzbauer et 
al., 1996). ARTN and PSPN were later identifi ed and isolated by database search and homology 
cloning (Baloh et al., 1998; Milbrandt et al., 1998). GDNF family ligands (GFLs) are distant 
members of transforming growth factor-β (TGF-β) superfamily carrying the typical conserved 
seven cysteine residues, and belong to the “cystine knot” proteins (Airaksinen and Saarma, 2002). 
Th ey function as disulfi de-bonded homodimers that are produced as precursors (prepro-form), 
and pro-GFLs are further processed before or aft er secretion into their mature, biologically 
active forms (Airaksinen and Saarma, 2002; Lonka-Nevalaita et al., 2010). GDNF is expressed in 
two forms that are generated by alternative splicing and contain diff erent pro-domains, (α)pro-
GDNF and (β)pro-GDNF (Suter-Crazzolara and Unsicker, 1994; Grimm et al., 1998). Secretion 
of the (β)pro-GDNF appears to be activity-dependent, while (α)pro-GDNF is secreted by the 
constitutive pathway (Lonka-Nevalaita et al., 2010).
2.3.1 GDNF family receptors and signaling
All four GFLs fi rst bind to their specifi c co-receptors, GDNF family receptor-α (GFRα) 1-4, that 
do not span the plasma membrane, but are either attached to it by a glycosyl phosphatidylinositol 
(GPI) anchor or aft er cleavage of the GPI-anchor exist in a soluble form (Airaksinen and Saarma, 
2002) (Figure 2.4). GDNF, ARTN and NRTN can also bind heparin sulfates in extracellular matrix 
(ECM) and cell membrane with high affi  nity (Bespalov et al., 2011). Th is limits their diff usion 
and distribution and may accumulate, store and immobilize them in high concentrations to 
certain locations, which likely has important implications for receptor binding and signaling. 
GDNF preferentially binds to GFRα1, NRTN to GFRα2, ARTN to GFRα3 and PSPN to GFRα4, 
but there is also signifi cant cross-reactivity between the GFLs and their co-receptors, although 
its physiological relevance is unclear (Figure 2.4). ARTN and PSPN co-receptors have not been 
found in the CNS and they presumably function only in the periphery. Aft er GFL binding to 
their specifi c co-receptors the complex binds to and activates the common signaling receptor 
tyrosine kinase Ret (rearranged during transfection) (Durbec et al., 1996; Jing et al., 1996; Trupp 
et al., 1996). Ligand binding causes homodimerization of two Ret molecules, their reciprocal 
trans-autophosphorylation of certain Ret intracellular tyrosine residues, and fi nally activation 
of signaling cascades (Airaksinen and Saarma, 2002). As a typical receptor tyrosine kinase, Ret 
spans through the cell membrane only once and has the enzymatically active kinase domain 
inside the cell (Figure 2.4). Th e phosphorylated tyrosine residues of Ret serve as docking sites 
for adapter proteins and enzymes that activate specifi c downstream cascades. Such signaling 
cascades include for example: phosphatidylinositol-3-kinase (PI3K)/Akt, phospholipase C-γ 
(PLCγ)/protein kinase C (PKC), Src kinase and Ras/extracellular-signal-regulated kinase (ERK) 
or mitogen–activated protein kinase (MAPK) pathways (Kramer and Liss, 2015).
Lipid raft s are ordered cell membrane microdomains that are enriched in sphingolipids, 
cholesterol and specifi c protein types, including GPI-anchored proteins (Simons and Sampaio, 
2011). Its GPI-anchor localizes GFRα1 to the lipid raft s (Figure 2.4), but Ret is excluded under 
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basal non-activated conditions (Tansey et al., 2000; Paratcha et al., 2001; Pierchala et al., 
2006). In vitro GDNF and GFRα1 together recruit Ret into the lipid raft s, which is important 
for subsequent downstream signal transduction (Tansey et al., 2000; Paratcha et al., 2001). 
Th e key importance of this mechanism for GDNF’s physiological functions was very recently 
demonstrated in vivo with a knock-in mouse model, where GFRα1 GPI anchor was replaced by 
a transmembrane domain that made GFRα1 unable to translocate to the lipid raft s (Tsui et al., 
2015). However, the transmembrane domain undoubtedly also inhibited the formation of soluble 
GFRα1, which can activate Ret outside the raft s (Airaksinen and Saarma, 2002). Th erefore, these 
novel mouse data are not specifi c enough to draw fi nal conclusions regarding the importance of 
lipid raft  localization. Furthermore, Ret and GFRα receptors may be co-localized in the same cell 
or expressed separately in projecting and target cells for signaling (Yu et al., 1998). Th is means 
that Ret can also interact with a GFRα receptor located in a separate cell (“in trans”).
Th roughout the brain GFRαs are much more widely expressed than Ret (Trupp et al., 1997; 
Yu et al., 1998), which suggests involvement of other Ret-independent signaling mechanisms. 
Indeed, GDNF/GRFα1 complex is reported to also signal through neural cell adhesion molecule 
(NCAM) (Paratcha et al., 2003) to activate focal cell adhesion kinase (FAK) and Fyn, which 
control neuronal migration and synapse formation (Paratcha and Ledda, 2008). GDNF signaling 
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Figure 2.4. Th e GDNF family of ligands and their receptors. Glial cell line-derived neurotrophic 
factor (GDNF), neurturin (NRTN), artemin (ARTN) and persephin (PSPN) bind preferentially their 
specifi c co-receptors GDNF family receptor α (GFRα) 1-4, although also signifi cant cross reactivity 
exists (thin arrows). Aft er that, the complex signals through the common receptor tyrosine kinase 
Ret or neural cell adhesion molecule (NCAM; GDNF only). GDNF can also bind to and signal 
through syndecan-3. Glycosyl phosphatidylinositol (GPI) anchor attaches GFRα receptors to the cell 
membrane, but the receptor also exists in a soluble form (sGFRα1). Figure modifi ed from Kramer & 
Liss 2015.
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is also shown to involve the heparan sulfate proteoglycan, syndecan-3 (Bespalov et al., 2011). In 
addition to direct intracellular signal activation, syndecan-3 might also act as a co-receptor that 
concentrates and presents GDNF molecules to Ret and GFRα1 (Bespalov et al., 2011). However, 
as Ret-defi cient midbrain dopamine neurons fail to respond to GDNF or NRTN, it is likely that 
Ret is the principal signaling receptor for these neurons (Taraviras et al., 1999). Further evidence 
from studies with Ret-transgenic mice, reviewed below, support this view.
2.3.2 Neuronal eﬀ ects of exogenous GDNF
According to earlier studies, dissociated embryonic dopamine neurons cultured with target 
cells (from striatum or PFC) grow target neuron-specifi c axons similarly to the in vivo target 
innervation (Hemmendinger et al., 1981). Culturing with striatal target cells also enhanced the 
phenotypic development, function and survival of dissociated dopamine neurons (Kotake et 
al., 1982; Hoff mann et al., 1983; Shalaby et al., 1983). Th ese studies suggest that the target cells 
secrete a trophic signaling molecule for dopaminergic neurons. Subsequently, conditioned media 
derived from rat B49 glial cell line, established almost 20 years earlier (Schubert et al., 1974), was 
shown to promote the survival and dopamine uptake of cultured embryonic dopamine neurons 
(Engele et al., 1991). Soon, GDNF was purifi ed and cloned at the biotechnology company 
Synergen from the same B49 glial cell line medium based on its ability to specifi cally support the 
survival and dopamine uptake of cultured dopaminergic neurons (Lin et al., 1993). In addition, 
recombinant GDNF increased neurite outgrowth and cell body size in these cultured neurons.
Remarkably, GDNF’s potential to treat dopaminergic neurodegeneration, characteristic 
of PD, was already suggested in this initial report. Th is notion was soon supported by the 
demonstration of its neurorestorative properties in a neurotoxin-based rat model of PD (Hoff er et 
al., 1994). Since then the neuroprotective and neurorestorative properties of GDNF therapy have 
been solidly established in various delivery paradigms and models of dopaminergic degeneration 
in rodents and primates (Beck et al., 1995; Sauer et al., 1995; Tomac et al., 1995a; Shults et al., 
1996; Cass, 1996; Gash et al., 1996, 2005; Bilang-Bleuel et al., 1997; Mandel et al., 1997; Tseng 
et al., 1997; Choi-Lundberg et al., 1997; Kearns et al., 1997; Rosenblad et al., 1998, 2000; Kirik 
et al., 2000b; Kordower et al., 2000; Kirik et al., 2000a; Georgievska et al., 2002b; Grondin et al., 
2002). Importantly, Kirik and coworkers showed that striatal administration of GDNF provides 
higher functional benefi ts compared to nigral delivery in 6-OHDA lesioned rats (Kirik et al., 
2000a), which is in line with the axonal die-back hypothesis (Burke and Malley, 2013). More 
recently it was shown that in a severe 6-OHDA lesion model the neurorestorative eff ect of GDNF 
is very modest (Voutilainen et al., 2011). Also, the failure of GDNF to provide neuroprotection in 
viral vector-mediated α-synuclein overexpression model of PD raised concerns on its effi  ciency 
in human PD (Lo Bianco et al., 2004; Decressac et al., 2011). However, it was subsequently 
demonstrated that this failure was due to downregulation of Nurr1 and consequently Ret by very 
strongly overexpressed α-synuclein and when Ret expression was restored by Nurr1 delivery, 
GDNF was eff ective in this model as well (Decressac et al., 2012a). It remains to be seen whether 
similar Ret and Nurr1 downregulation also happens in human PD and whether it contributes to 
the disease progression.
Exogenous GDNF has been shown to also support the survival of motoneurons (Henderson 
et al., 1994; Oppenheim et al., 1995; Yan et al., 1995), peripheral sympathetic neurons (Ebendal 
et al., 1995), noradrenergic neurons (Arenas et al., 1995), parasympathetic neurons (Buj-Bello 
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et al., 1995), sensory neurons (Buj-Bello et al., 1995; Matheson et al., 1997), Purkinje cells from 
cerebellum (Mount et al., 1995) and basal forebrain cholinergic neurons (Williams et al., 1996). 
An important part of the neuroprotective and restorative properties of GDNF is undoubtedly 
its ability to inhibit apoptosis, as was shown in postnatal cultured dopaminergic neurons (Burke 
et al., 1998). Remarkably, GDNF was the only trophic factor among the nine tested in the study 
that was able to support the survival of postnatal dopamine neurons in vitro, even though the 
other factors had previously shown eff ects in embryonic cultures (Burke et al., 1998). In support 
of its anti-apoptotic properties, striatal GDNF delivery suppressed postnatal apoptotic cell 
death of nigrostriatal dopamine neurons during the fi rst, but not the second phase of natural 
developmental cell death of these neurons (Oo et al., 2003). Furthermore, GDNF neutralizing 
antibodies had an opposite eff ect in this study (Oo et al., 2003). Ectopic striatal transgenic 
overexpression of GDNF also increased the number of nigrostriatal dopamine neurons surviving 
the fi rst phase of developmental cell death, but these changes did not persist to adulthood 
(Kholodilov et al., 2004). Using a viral vector approach the group provided further evidence 
that PI3K/Akt signaling would mediate the anti-apoptotic eff ects of exogenous GDNF during 
the natural cell death period of dopamine neurons (Ries et al., 2009). How endogenous GDNF 
regulates the developmental survival of dopamine neurons is currently not clear.
Injected GDNF protein is retrogradely transported from the striatum to the dopaminergic 
cell bodies that reside in the SNpc (Tomac et al., 1995b). Similarly, aft er gene delivery by a viral 
vector GDNF protein is transported to the SNpc (Georgievska et al., 2002b). Th is allows striatal 
delivery of GDNF to have specifi c eff ects also in the cell body that is located too far away for 
GDNF to reach via mere diff usion.
In addition to the robust trophic actions on injured dopamine neurons, GDNF delivery 
appears to have profound eff ects on intact midbrain dopamine systems. Nigral GDNF injection 
in adult rats increased spontaneous activity and decreased food consumption (Hudson et al., 
1995). Th ese behavioral eff ects were associated with increased nigral, but reduced striatal, 
dopamine levels and increased dopamine turnover in both compartments (Hudson et al., 1995). 
Th ese fi ndings were replicated by others in rats (Hebert et al., 1996; Martin et al., 1996) and 
largely in monkeys (Gash et al., 1995), but were also reported not to replicate in adult rats by 
one group (Beck et al., 1996). In addition, amphetamine-induced locomotor activity (Hudson 
et al., 1995) and dopamine release (Hebert et al., 1996) were increased in rats aft er nigral GDNF 
delivery. Similarly, striatal dopamine release was augmented aft er K+ stimulation in rats (Hebert 
et al., 1996) and monkeys (Gash et al., 1995) aft er nigral GDNF delivery. Chronic ventricular 
GDNF delivery in aged (over 20 years old) monkeys increased K+ and amphetamine stimulated 
dopamine release and improved hand motor functions (Grondin et al., 2003). Together these 
results overall suggest that ectopic GDNF enhances dopamine signaling in the nigrostriatal 
system. Th is is further supported by the fi ndings that GDNF exposure in vitro increased vesicular 
dopamine content by 380 % and consequently the amount of dopamine released (Pothos et 
al., 1998). In addition, GDNF acutely inhibits A-type K+ channels in the midbrain dopamine 
neurons through the MAPK pathway leading to enhanced excitability of these neurons (Yang 
et al., 2001). GDNF also promotes formation of new functional dopaminergic axon terminals 
(Bourque and Trudeau, 2000).
Many of the reported eff ects on dopamine transmission are closely related to GDNF’s ability 
to regulate dopamine synthesis through TH. Two-week GDNF infusion to the SN transiently 
reduced TH immunoreactivity in non-lesioned rats (Lu and Hagg, 1997). GDNF injection (10 
μg) to the SN/VTA region caused 30 % and 60 % reductions in TH gene expression and mRNA 
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levels in VTA and SN, respectively (Messer et al., 1999). Additionally, striatal 13 months-long 
viral vector-mediated overexpression of GDNF up to 100 fold over the basal levels reduced 
cellular TH mRNA by 70 % and 40 % in the SNpc and VTA, respectively (Rosenblad et al., 
2003). TH immunoreactivity in the striatum was also reduced up to 50 %, while dopaminergic 
terminals appeared to be unchanged (Rosenblad et al., 2003). Th is suggests that in an intact 
striatum GDNF does not cause aberrant sprouting, where dopaminergic neurites grow towards 
the GDNF source, unlike what happens aft er treating neurotoxin-induced damage (Kirik et al., 
2000a, 2000b; Georgievska et al., 2002a). It has been hypothesized that the TH downregulation 
might be part of a regenerative response initiated by GDNF, as injured neurons switch their 
protein synthesis from functional to regenerative molecules (Grafstein, 1975).
However, it may be more likely that TH downregulation is a result of TH feedback 
inhibition by dopamine as GDNF, at least initially, enhances dopamine synthesis and release. 
TH downregulation may also be considered as a side eff ect of exogenous GDNF delivery. GDNF 
was shown to increase TH activity in vitro through phosphorylation of its serine 31 and 40 
residues in rat and human cell lines (Kobori et al., 2004). Th is was confi rmed in vivo in a study 
where striatal GDNF delivery in 24 month old rats reduced striatal TH levels but increased TH 
phosphorylation on serine 31, 40 and 19 residues (Salvatore et al., 2004). Nigral TH levels were 
unaltered, but serine 31 phosphorylation was specifi cally and strongly increased. Th ese changes 
were associated with enhanced dopamine release aft er K+ and amphetamine stimulation in 
microdialysis experiments (Salvatore et al., 2004). However, it remains somewhat questionable 
which of the TH phosphorylation eff ects reported in these studies are direct and specifi c to 
GDNF and which ones indirect and secondary, especially as the GDNF dose utilized was very 
high (100 μg compared to 10 μg normally used in rats) (Salvatore et al., 2004).  In support of this 
notion, many of the fi ndings did not repeat similarly in a follow-up study and the lower GDNF 
dose (30 μg) only elevated serine 31 phosphorylation in the striatum (Salvatore et al., 2009).
As mentioned above, the initial study on GDNF reported its ability to stimulate dopamine 
uptake in vitro (Lin et al., 1993). However, the exact eff ects of exogenous GDNF on DAT 
function have remained obscure. It appears that GDNF’s eff ects on DAT expression levels play 
only a minor role, as only a very high dose of striatally delivered GDNF (100 μg) reduced DAT 
levels, while a high dose of 30 μg had no eff ect (Salvatore et al., 2009). Similarly, viral delivery of 
GDNF to the dSTR was reported not to have eff ects on total DAT levels or its compartmental 
distribution but was reported to decrease dopamine uptake (Barroso-Chinea et al., 2016). Th is 
was associated with formation of DAT dimers and increased DAT interaction with α-synuclein 
(Barroso-Chinea et al., 2016). Recently, strong evidence was provided that endogenous GDNF 
through Ret reduces DAT activity by promoting its removal from the plasma membrane via 
direct interaction involving endocytosis mediator Vav2 (Zhu et al., 2015). Interestingly, this 
mechanism was reported to be specifi c for the ventral part of the striatum (Zhu et al., 2015). 
Hence, GDNF’s eff ects on dopamine reuptake appear to be complex, region-specifi c and involve 
multiple mechanisms, but may also depend on GDNF source and dose. Clearly, more research is 
needed to uncover how GDNF infl uences striatal DAT function.
In conclusion, exogenous GDNF promotes dopamine neuron survival, growth and 
phenotype, which appear to underlie most of its functional eff ects in intact and lesioned animals. 
However, it is questionable whether these eff ects refl ect the role of endogenous GDNF in the 
development, maintenance and function of midbrain dopamine neurons. Especially, the eff ects 
of huge doses of GDNF may be qualitatively very diff erent from endogenous GDNF, whose 
expression levels and patterns are carefully regulated. Additionally, the commonly used E. coli 
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-produced GDNF may have diff erent biological activity compared to mammalian GDNF due to 
folding issues and diff erent post-translational modifi cations.
2.3.3 Endogenous GDNF and the midbrain dopamine systems
Despite being called “glial cell line-derived”, in the brain and in the striatum GDNF is not 
synthetized by glial cells. Early studies discovered that throughout the striatum GDNF mRNA is 
only expressed by diff usely scattered medium-sized neurons (Trupp et al., 1997; Oo et al., 2005). 
Only relatively recently it was discovered that nearly 95 % of GDNF expressing neurons in the 
mouse striatum are PV+ interneurons, the rest ~5 % being cholinergic or SOM+ interneurons 
(Hidalgo-Figueroa et al., 2012). Furthermore, it was shown that striatal GDNF expression peaks 
around P15 in mouse, being lower in young adults and much lower just aft er birth (Hidalgo-
Figueroa et al., 2012). GDNF mRNA is prominently expressed in the nervous system throughout 
mouse embryonic development and in adulthood, while the expression of its receptors is more 
limited (Golden et al., 1999). Th e dramatic segregation of expression of GDNF and its receptors 
indicates that GDNF functions as an endogenous target-derived neurotrophic factor in the brain 
(Trupp et al., 1997; Golden et al., 1999). Highest GDNF expression in the adult brain is found in 
the striatum, nucleus accumbens, septum and thalamus (Trupp et al., 1997; Hidalgo-Figueroa et 
al., 2012). GDNF is also expressed in various non-neuronal organ systems in the body (Nosrat 
et al., 1996; Suvanto et al., 1996; Golden et al., 1999) and in general GDNF expression is much 
higher in the peripheral organs than in neuronal tissues (Suvanto et al., 1996; Trupp et al., 1997). 
Th is most likely refl ects the critical role GDNF has in the correct development and function of 
those organs.
Mice completely lacking GDNF die within 24 hours aft er birth due to absence of kidneys 
and enteric neurons, but with intact midbrain dopamine systems (Moore et al., 1996; Pichel et 
al., 1996; Sánchez et al., 1996). Th e same phenomenon also happens to the null mice for GFRα1 
(Cacalano et al., 1998; Enomoto et al., 1998) and Ret (Schuchardt et al., 1994), but not to the 
mice lacking other GFLs or their co-receptors (reviewed in Airaksinen & Saarma 2002). Th is 
indicates that GDNF/GFRα1/Ret complex signaling has the key infl uence in the development of 
these peripheral organs. However, as the natural cell death period and maturation of midbrain 
dopamine neurons happens primarily aft er birth (Oo and Burke, 1997; Jackson-Lewis et al., 
2000), the intact dopamine system in newborn GDNF null mice does not exclude the possibility 
that GDNF would have an important physiological role in the development and maintenance of 
these neurons.
Th e lethality of full GDNF knock-out mice still permits studies with heterozygous GDNF 
mice. Several groups have investigated the alterations in the dopamine systems of these mice 
that have only one functional GDNF allele. Gerlai and coworkers (2001) found no changes in 
striatal tissue levels of dopamine and DOPAC or in spontaneous or amphetamine-stimulated 
locomotion in 4-8 months old GDNF heterozygous mice, but reported an impairment in the 
water maze learning task (Gerlai et al., 2001). Similarly Airavaara et al. (2006) saw no diff erences 
in striatal tissue dopamine, DOPAC and HVA levels or in spontaneous or cocaine-stimulated 
locomotion in 3 months old GDNF heterozygous mice (Airavaara et al., 2006). However, they 
detected increased extracellular dopamine levels in striatum and nucleus accumbens and altered 
responses to morphine in these mice (Airavaara et al., 2004, 2006). In line with these fi ndings, 
Heermann and colleagues (2010) found no changes in striatal dopamine, DOPAC and HVA 
levels, in SNpc TH+ cell numbers or in striatal TH+ optical density in 20-24 months old GDNF 
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heterozygous mice or even in GDNF/TGFβ double heterozygous mice (Heermann et al., 2010). 
However, in striking contrast to the above studies Boger et al. (2007) reported increased striatal 
tissue levels of dopamine and DOPAC at 3 months of age, but reduced levels at 12 months of age 
together with diminished spontaneous locomotor activity in GDNF heterozygous mice (Boger et 
al., 2007). Th ey also reported reduced TH+ SNpc cell number and striatal TH+ optical density 
along with reduced performance in accelerating rotarod in aged mice (Boger et al., 2006). Finally, 
they reported enhanced striatal dopamine uptake without changes in DAT levels, which may 
have contributed to the enhanced susceptibility to methamphetamine toxicity and enhanced 
nomifensine-induced locomotion in these mice (Boger et al., 2007; Littrell et al., 2012). In 
conclusion, the results from studies with GDNF heterozygous mice are highly controversial, but 
generally suggest subtle changes in dopamine neuron function, which may be age-related.
In addition to the above studies with GDNF heterozygous mice, one study reported a 
dramatic impact of a further 20 % reduction in adult GDNF expression down to 40 % of wild-
type levels (Pascual et al., 2008). Th ey generated GDNF conditional knock-out (cKO) or “fl oxed” 
mice, crossed these animals to Esr1-Cre transgenic line and injected tamoxifen at two months of 
age to activate Cre recombinase and hence to trigger GDNF deletion (Pascual et al., 2008). Th e 
resulting reduction in endogenous GDNF levels was reported to cause massive degeneration of 
SNpc and VTA dopaminergic neurons (60-70 % loss at 7 months aft er tamoxifen injections) and 
almost complete disappearance of brain noradrenergic neurons that reside in locus coeruleus 
(Pascual et al., 2008). Th e animals were also reported to develop hypokinesia (Pascual et al., 
2008).
In the absence of follow-up studies with genetic GDNF models, Ret cKO mice have 
provided indirect in vivo evidence regarding GDNF’s physiological role. Conditional deletion of 
Ret receptor from dopaminergic (DAT+) neurons caused no alterations in the number of TH+ 
cells in SNpc and VTA nor in TH+ optical density in the striatum or nucleus accumbens at 8-12 
months of age (Jain et al., 2006). Th ere were no diff erences in either striatal levels of dopamine 
or its metabolites or in behavioral tests measuring motor performance (Jain et al., 2006). Th e 
authors concluded that Ret is dispensable for the development and maintenance of midbrain 
dopamine neurons. However, another group that had followed similar mice until very old age 
(up to 24 months) detected late and progressive degeneration in the nigrostriatal dopaminergic 
system (Kramer et al., 2007). Th eir comprehensive characterization of these mice indicated 
that Ret-defi cient dopaminergic fi bers progressively degenerate in the striatum from 9 months 
onwards, their loss being most pronounced (over 50 %) at 24 months of age (Kramer et al., 2007). 
Th is was accompanied by similarly progressive loss of dopaminergic cell bodies in SNpc (no 
change at 3 months, ~25% loss at 12 and 38 % loss at 24 months), but not in the VTA (Kramer et 
al., 2007). Also, the noradrenergic neurons in the locus coeruleus remained intact when Ret was 
deleted from the entire CNS (Kramer et al., 2007). Th e degenerative changes were accompanied 
by reactive gliosis in the dorsal striatum and a neuroinfl ammatory response in the SNpc at 24 
months, but with no changes in nigral α-synuclein levels (Kramer et al., 2007). Dopamine release 
and reuptake were both reduced at 12 and 24 months of age (Kramer et al., 2007). Surprisingly, 
the reported degenerative changes did not aff ect striatal levels of dopamine and DOPAC, 
spontaneous locomotor activity or motor performance in the accelerating rotarod (Kramer et 
al., 2007). A follow-up study found that these mice do not display increased sensitivity to the 
dopaminergic neurotoxin MPTP, but the recovery of their dopaminergic fi bers in the striatum is 
impaired compared to the controls (Kowsky et al., 2007). Together these results suggest a role for 
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Ret signaling in the long-term maintenance of nigrostriatal dopamine system and in recovery of 
striatal dopaminergic axonal terminals aft er injury.
Further evidence about the signifi cance of Ret signaling comes from  studies with knock-in 
multiple endocrine neoplasia type B (MEN2B) mice, where a single point mutation (Met918Th r) 
renders the intracellular tyrosine kinase domain of Ret constitutively active (Takahashi, 2001). 
Although originally developed as a cancer model (Smith-Hicks et al., 2000), these mice were 
shown to have greatly increased levels of dopamine and its metabolites in dorsal and ventral 
striatum (up to 100 % elevation in homozygous mice), cortex and hypothalamus at 2-3 months 
of age (Mijatovic et al., 2007). Th is was accompanied by increased levels of striatal TH and 
DAT as well as by modestly increased numbers of TH+ neurons in SNpc (but not in VTA) and 
DAT+ terminals in the striatum (Mijatovic et al., 2007). Finally, their spontaneous locomotor 
activity was reduced, but cocaine-stimulated activity was augmented (Mijatovic et al., 2007). In 
follow-up studies these mice were shown to have increased dopamine synthesis, storage, release 
and reuptake in the striatum (Mijatovic et al., 2008) and they were shown to be protected against 
the dopaminergic neurotoxin 6-hydroxydopamine (6-OHDA) (Mijatovic et al., 2011).
Contrarily to the Ret-defi cient mice, the results from MEN2B mice suggest a potential role 
for Ret signaling in the development, function, protection and maintenance of the nigrostriatal 
dopaminergic system. Th ere are several possible explanations for this discrepancy. Both the 
complete removal of Ret from dopaminergic neurons and the unnaturally strong and continuous 
Ret activation may trigger secondary, compensatory mechanisms that mask or confound the 
primary eff ects of the genetic manipulations. Furthermore, when drawing conclusions from 
these Ret mutants to endogenous GDNF it is important to note that all the GDNF family ligands 
signal through Ret, so the observed alterations can represent actions of separate ligands. GDNF 
is reported to also signal Ret-independently (Paratcha et al., 2003; Bespalov et al., 2011), so 
endogenous GDNF might have additional eff ects to those suggested by the Ret mutant mice. 
Hence, the current data regarding endogenous GDNF is incomplete, at least in part controversial 
and only partially in line with studies using exogenous GDNF. Novel animal models are needed 
to resolve GDNF’s role as a regulator of midbrain dopamine neurons.
2.3.4 Exogenous GDNF and NRTN in human clinical trials
Th e promising preclinical results have taken GDNF protein to three phase 1 and two phase 2 
clinical trials with human PD patients. NRTN has also been tested using gene therapy in one 
phase 1 and two phase 2 clinical trials based on its ability to protect and rescue dopamine 
neurons in animal models of PD (Oiwa et al., 2002; Kordower et al., 2006; Gasmi et al., 2007). 
As polypeptides, neurotrophic factors are quickly degraded aft er oral administration and do not 
cross the blood-brain barrier. Hence, they need to be delivered directly into the brain.
In the fi rst phase 2 study GDNF protein was delivered to the lateral ventricle of advanced PD 
patients without achieving clinical benefi t but rendering various systemic adverse eff ects (Nutt 
et al., 2003). It was subsequently found that GDNF failed to reach the target tissues putamen 
(striatum) and SN (Kordower et al., 1999; Nutt et al., 2003). Consequently, intracerebroventricular 
delivery route was abandoned.
To the contrary, direct 12-month long striatal delivery of GDNF in two phase 1 studies 
was found safe (Gill et al., 2003; Slevin et al., 2006). However, the subsequent double-blind, 
placebo-controlled trial was stopped prematurely at 6 months due to lack of effi  cacy (Lang et al., 
2006). Th ere is clear evidence that the diff erent pump and catheter used in this study resulted in 
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insuffi  cient distribution of GDNF throughout the putamen to provide clinical benefi ts (Salvatore 
et al., 2006; Morrison et al., 2007).
To improve the distribution of the trophic factor in the target region and achieve more 
convenient and sustained delivery, the recent focus has been in viral vector-mediated delivery. 
An open-label study with bilateral adeno-associated virus type 2 (AAV2) delivery of NRTN 
to putamen of 12 advanced PD patients reported very good safety and tolerability as well as 
improved motor function at 1 year (Marks et al., 2008). However, a double-blind, sham-surgery 
controlled 12-month phase 2 trial with 58 advanced PD patients showed no signifi cant benefi t 
compared to controls at 12 months, but the procedure itself was again well tolerated (Marks et 
al., 2010). However, the study showed modest, but signifi cant benefi ts at 18 months for AAV2-
NRTN treatment, although this sample of patients was much smaller (Marks et al., 2010). In 
addition, even though the striatal distribution of NRTN in the PD patients was comparable to 
that observed in similarly treated MPTP-lesioned monkeys, nigral NRTN expression was nearly 
absent in PD patients while in the monkey model it was prominent (Bartus et al., 2011, 2015). 
Th is suggests poor NRTN diff usion and impaired axonal transport of NRTN to the SNpc in the 
PD patients. To test this possibility an 18-month double-blind, sham-controlled trial with 51 
advanced PD patients was conducted using higher AAV2-NRTN doses and bilateral delivery 
to both putamen and SNpc. However, this study did not report signifi cant benefi ts compared to 
the sham surgery, even though the treatment was again safe and well tolerated (Olanow et al., 
2015). Nevertheless, a subgroup of less advanced PD patients, diagnosed within 5 years prior to 
the treatment, appeared to respond better to the treatment compared to more advanced patients 
(Olanow et al., 2015).
In conclusion, so far no double-blind phase 2 trial with GDNF or NRTN has demonstrated 
clear clinical benefi ts to patients with advanced PD. Th ere are many possible reasons for these 
failures, despite the repeated success in animal models. Impairment of axonal transportation and 
possible lack of anterograde transportation might hamper the movement of trophic factors from 
the striatum to the SNpc as well as the transmission of survival and growth signals from SNpc 
to the striatum (Olanow et al., 2015). Dopamine neurons in advanced PD patients may be too 
few or too dysfunctional to respond to the treatment (Kordower et al., 2013) and hence earlier 
disease stage patients should benefi t more from the trophic factor therapy. Adequate delivery 
and diff usion of the trophic factors may pose a general problem in the large human brain 
compared to the smaller brains of rodents and rhesus monkeys. In addition, there is currently 
poor understanding of the roles that endogenous neurotrophic factors play in aging and diseased 
dopamine neurons. Additional clinical studies with trophic factors are still underway, including 
AAV2 gene delivery of GDNF and continuous GDNF infusion into the putamen (Olanow et al., 
2015). However, better understanding and utilization of the general cell biology knowledge of 
GFLs will be most likely needed to improve therapeutic success of GDNF-based therapies, like 
small molecular weigh GDNF-mimetics.
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3 AIMS OF THE STUDY
Despite intensive research on the in vivo eff ects of exogenous GDNF, the role of endogenous 
GDNF in the development, maintenance and function of the midbrain dopamine neurons 
remains largely unknown. With the novel GDNF animal models, we aimed to clarify the role of 
physiological GDNF in the development, maintenance and function of the midbrain dopamine 
neurons.
Th e specifi c aims of the study were: 
1. Investigate the role of endogenous GDNF in the maintenance of nigrostriatal 
dopaminergic system during development and early postnatal maturation (Studies I 
and III)
2. Clarify the role of endogenous GDNF in the maintenance of midbrain dopamine 
systems during aging (Studies I and III)
3. Characterize the eff ects of endogenous GDNF on dopamine levels, release and reuptake 
(Studies II and III)
4. Examine the ability of endogenous GDNF to protect nigrostriatal dopamine system 
from neurotoxic lesions (Study III)
Aims of the Study
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4 MATERIALS AND MAIN METHODS
4.1 New GDNF animal models
4.1.1 GDNF condiƟ onal knock-out mice
In order to circumvent the problem of early lethality in mice without GDNF (Moore et al., 
1996; Pichel et al., 1996; Sánchez et al., 1996), we used Cre-Lox recombination technology to 
develop a mouse strain where GDNF can be conditionally deleted to preserve its vital role in the 
development of peripheral organs. Gdnf exon 3, which encodes for the mature GDNF protein, 
was fl anked with specifi c LoxP sequences that the virus-derived enzyme Cre can recognize 
(Study I, Figure 1a). Th is resulted in the Gdnf “fl oxed” mice. When Cre is expressed in a cell, 
it permanently cleaves away DNA between the two LoxP sites and rejoins the remaining DNA 
strands back together. Hence, by controlling Cre expression in the Gdnf fl oxed mice, we could 
specify where and when Gdnf is deleted.
GDNF exon 3 was conditionally deleted by three complementary approaches: (i) Crossing 
the fl oxed mice to transgenic Nestin-Cre line (Tronche et al., 1999; Kramer et al., 2007) results 
in removal of GDNF from the entire central nervous system (CNS) around E10. (ii) Unilateral 
injection of adeno-associated virus serotype 5 encoding Cre (AAV5-Cre) into dorsal striatum 
(dSTR) of 2 months old fl oxed mice removes GDNF specifi cally from this innervation target of 
nigrostriatal dopamine neurons. (iii) Crossing the fl oxed mice to Esr1-Cre line where Cre activity 
can be used upon tamoxifen (TMX) application (Hayashi and McMahon, 2002). Using a similar 
GDNF fl oxed allele and the same Esr1-Cre line, Pascual et al. reported that  intraperitoneal (i.p.) 
tamoxifen (TMX) injections (200 mg/kg per day for four days) at two months of age cause a 
signifi cant 60 % reduction in the brain GDNF levels (Pascual et al., 2008). To replicate Pascual et 
al. experiments, we used the same injection protocol (Pascual et al., 2008).
In the case of Nestin-Cre and Esr1-Cre lines we studied compound heterozygous mice with 
one regular knock-out allele (KO) and one fl oxed allele (F) for Gdnf as in (Kramer et al., 2007; 
Pascual et al., 2008). All the mouse lines (including GDNF hypermorphic mice below) were kept 
in a triple mixed 129Ola/ICR/C57bl6 genetic background. Th ey were housed in 12/12 light/dark 
cycle with “lights-on” at 06:00, at ambient temperature of 20–22 °C, 2–5 animals per cage with 
ad libitum access to regular chow and tap water. All animal experiments were authorized by the 
National Animal Experiment Board of Finland.
4.1.2 GDNF hypermorphic mice
GDNF hypermorphic (GDNFh) mice represent a novel type of genetically modifi ed animal 
model. In these mice, the physiological GDNF expression is enhanced, but the gene 5’ 
regulatory region, exon and introns remain intact following the regulatory control of native 
promoters and enhancers. Th e endogenous 3’ untranslated region (3’UTR) of Gdnf gene was 
replaced by a construct (puΔtk cassette; Study III, Figure 1) that renders the resulting mRNA 
largely unresponsive to the negative microRNA (miRNA) regulation that destabilizes the native 
Gdnf mRNA. Increased mRNA stability allows more of native GDNF protein to be produced 
everywhere in the body where and when GDNF is normally expressed. Hence, the normal 
temporal and spatial pattern of Gdnf expression is retained.
As the homozygous GDNFh animals die by two weeks of age due to kidney defects (Study 
III, Figure 2F-I) we conducted all our adult studies with heterozygous GDNFh mice.
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4.2 Main methods
Th e main methods used in this study are listed in Table 4.1. Detailed descriptions of materials 
and methods can be found in the original publications and their supplements, which are referred 
to by their Roman numerals.
Table 4.1. Methods used.
Method Used in Author personally involved
Amphetamine-induced locomoƟ on II, III II, III
Brain dissecƟ on I, II, III I, II, III
Corridor test I, III III
DeterminaƟ on of monoamines I, II, III I, II, III
Fast-scan cyclic voltammetry II, III
GDNF ELISA I, III
Immunohistochemistry I, III I, III
In vivo chronoamperometry II, III
In vivo microdialysis II, III II, III
Membrane protein bioƟ nylaƟ on II
OpƟ cal densitometry analysis I, III I
QuanƟ taƟ ve PCR I, III
Stereological analysis I, III I, III
StereotacƟ c surgery I, II, III II, III
Transcardiac perfusion I, III I, III
Western bloƫ  ng II, III
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5 RESULTS
5.1 Brain GDNF expression in GDNF condiƟ onal knock-out 
mice (Study I)
GDNF messenger RNA (mRNA) measurements revealed that GDNF expression was either absent 
or very low in the presence of Cre in all the ‘fl oxed’ mouse strains (Figure 5.1). In adult Nestin-
Cre animals (F/KO + Nestin-Cre) GDNF mRNA was virtually absent in the dopaminergic brain 
regions investigated, while the heterozygous animals (C/KO) had only ~50 % reduction (Figure 
5.1a). Intrastriatal injection of AAV5-Cre caused nearly full GDNF deletion in the injected 
striatum by 9 months aft er injection (Figure 5.1b). At the age of 5 months, i.e. 3 months aft er 
TMX injections Esr1-Cre mice had around 85 % reduction in the whole brain GDNF mRNA 
levels, but unexpectedly this appeared to happen independently of TMX (Figure 5.1c). At two 
months of age these animals still had normal GDNF mRNA levels (Study I, Figure 3b). 
Figure 5.1. Relative levels of Gdnf mRNA in GDNF cKO mice. (a) Gdnf mRNA levels were halved 
in C/KO animals and were virtually absent in F/KO + Nestin-Cre in all the brain areas studied. (b) 
Striatal AAV5-Cre injection did not have an eff ect on C/C mice, but in F/F animals Gdnf mRNA was 
nearly absent in the injected striatum. (c) Gdnf mRNA levels were halved in F/KO brain and greatly 
reduced in F/KO + Cre. TMX injections did not have an eff ect on Gdnf expression levels. F-fl oxed; 
KO-knock-out; C-control containing both wild-type and fl oxed alleles, except for AAV5-Cre only 
wild-type alleles; dSTR-dorsal striatum; SN-substantia nigra; VTA-ventral tegmental area; n.a. = not 
applicable; TMX-tamoxifen; *, *** p < 0.05 or 0.001 relative to C/C, ##, ### p < 0.01 or 0.001 relative 
to C/KO. Kruskal-Wallis test with stepwise-stepdown multiple comparison and two-way ANOVA 
were used for statistical analysis. Error bars are mean ± s.e.m.
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5.2 TH-posiƟ ve cell numbers in GDNF condiƟ onal knock-out 
mice (Study I)
Despite the removal or clear reduction of GDNF mRNA expression, stereological analysis of 
TH+ cells indicated no alterations in the numbers of dopaminergic neurons in the SNpc, even 
aft er aging (Figure 5.2). Nestin-Cre mice were studied at the ages of 3, 14 and 19 months  (Figure 
5.2a) and AAV5-Cre and Esr1-Cre mice at the age of 9 months; 7 months aft er their respective 
injections (Figure 5.2b and c). VTA was also analyzed in 19 months old Nestin-Cre mice without 
detecting signifi cant diff erences (Figure 5.2a). Finally, TH+ optical density in dSTR and ventral 
striatum (vSTR) was unchanged in Nestin-Cre mice (Study I, Figure 1g).
Figure 5.2. Midbrain TH+ cell numbers in GDNF cKO mice. (a) Th ere were no diff erences in 
TH+ cell numbers between the genotypes in SNpc or VTA in Nestin-Cre mice. (b) Th ere were no 
diff erences in SNpc TH+ cell numbers between the intact and AAV5-Cre injected side. (c) Th ere 
were no diff erences between the groups in SNpc TH+ cell numbers in Esr1-Cre mice. TH-tyrosine 
hydroxylase; F-fl oxed; KO-knock-out; C-control containing both wild-type and fl oxed alleles, except 
for AAV5-Cre only wild-type alleles; SNpc-substantia nigra pars compacta; VTA-ventral tegmental 
area; TMX-tamoxifen. Error bars are mean ± s.e.m.
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5.3 Monoamine concentraƟ ons in diﬀ erent brain areas of 
GDNF condiƟ onal knock-out mice (Study I and II)
In line with the TH+ cell counts and striatal TH+ optical density analysis there were no 
diff erences in the brain tissue levels of dopamine or its metabolites DOPAC and HVA in Nestin-
Cre GDNF cKO strain or in AAV5-Cre injected mice. Table 5.1 summarizes the average levels of 
these monoamines in dSTR, vSTR, SN) and VTA in Nestin-Cre line and in dSTR of AAV5-Cre 
injected mice. Th ere were no diff erences in dopamine turnover [(DOPAC+HVA)/dopamine] in 
any brain area (unpublished data).
Table 5.1 Cerebral tissue concentrations of dopamine, DOPAC and HVA (ng/g of wet tissue) in 
Nestin-Cre and AAV5-Cre lines.
NesƟ n-Cre
Dorsal striatum
C/C
C/KO
C/KO + NesƟ n-Cre
Ventral striatum
C/C
C/KO
C/KO + NesƟ n-Cre
SubstanƟ a Nigra
C/C
C/KO
C/KO + NesƟ n-Cre
Ventral tegmental area
C/C
C/KO
C/KO + NesƟ n-Cre
Dopamine
14 206±957
14 598±1 099
14 476±1 020
9 527±755
9 276±594
9 690±514
253±25
233±22
245±34
598±39
589±29
610±43
DOPAC
552±91
485±59
422±72
437±48
394±34
409±40
80±11
77±6
70±12
189±20
229±27
200±12
HVA
240±34
395±105
502±143
171±44
121±30
173±35
59±9
59±12
72±24
136±40
99±17
153±43
AAV5-Cre 
Dorsal striatum
C/C
C/C + AAV5-Cre
C/F
C/F + AAV5-Cre
F/F
F/F + AAV5-Cre
Dopamine
10 756±910
10 444±1 082
11 233±451
11 304±599
10 719±850
10 866±718
DOPAC
820±98
973±168
955±83
781±78
791±83
834±82
HVA
348±93
262±59
373±73
345±68
401±83
428±76
Average ± SEM
30
Results
5.4 Amphetamine eﬀ ects on  NesƟ n-Cre GDNF condiƟ onal 
knock-out mice (Study II)
Even though the numbers of TH+ cells and brain dopamine levels were unchanged in Nestin-
Cre GDNF cKO mice that lack brain GDNF, these mice respond diff erently to amphetamine 
compared to their GDNF-expressing littermates (Figure 5.3). Amphetamine enters dopaminergic 
terminals via DAT, displaces dopamine from the storage vesicles and causes DAT-dependent 
dopamine effl  ux to the extracellular space (German et al., 2015). Amphetamine also directly 
inhibits DAT function, which contributes to the increased extracellular dopamine levels and the 
consequent psychomotor stimulation (German et al., 2015). Amphetamine-induced (1 mg/kg, 
i.p.) hyperlocomotion was blunted in the absence of brain GDNF (Figure 5.3a). As amphetamine 
response is unaltered in GDNF heterozygous mice (Gerlai et al., 2001), we compared F/KO + 
Nestin-Cre mice only to their C/KO littermates to have large enough groups. Th e blunted 
psychomotor stimulation appears to be due to reduced amphetamine-induced dopamine effl  ux 
through DAT, which was determined by cyclic voltammetry in striatal slices (Figure 5.3b). In the 
absence of brain GDNF striatal DAT seems more resilient to reverse from pumping dopamine 
into the cells to releasing the cytosolic dopamine into the extracellular space as happens in the 
presence of amphetamine (Figure 5.3c). Th e baseline open fi eld activity was unchanged in these 
mice (Study I, Supplementary Table 1). Furthermore, amphetamine depleted synaptic vesicles 
similarly in the presence and absence of brain GDNF (Study II, Supplementary Figure 1a).
Figure 5.3. Amphetamine eff ects on Nestin-Cre GDNF cKO mice. (a) Open fi eld locomotor activity 
aft er amphetamine injection (1 mg/kg) showed reduced hyperlocomotion in the absence of brain 
GDNF. (b)  Dopamine effl  ux caused by amphetamine was signifi cantly attenuated in striatal slices in 
the absence of brain GDNF. (c) In the absence of brain GDNF it took nearly twice as long for DAT 
to reverse the direction of dopamine fl ow aft er adding amphetamine on the striatal slices. F-fl oxed; 
KO-knock-out; C-control containing both wild-type and fl oxed alleles; DAT-dopamine transporter. 
*, p < 0.05 relative to C/C. One-way ANOVA for repeated measures and Kruskal-Wallis test followed 
by Mann-Whitney U post hoc tests and Bonferroni correction were used for statistical analysis. Error 
bars are mean ± s.e.m.
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5.5 Dopamine release and uptake in the absence of brain 
GDNF (Study II)
Th e interesting results with amphetamine encouraged us to investigate dopamine release and 
uptake in Nestin-Cre GDNF cKO mice. Single pulse -stimulated dopamine release was similar 
between the genotypes when measured by cyclic voltammetry in striatal slices (Figure 5.4a). 
However, dopamine uptake was augmented in the absence of brain GDNF as determined by 
chronoamperometric studies in anesthetized animals  (Figure 5.4b). Cyclic voltammetry studies 
in striatal slices also supported this fi nding  (Study II, Figure 2C-F). We found increased DAT 
tissue levels in the dSTR of Nestin-Cre GDNF cKO mice with a smaller increase in C/KO 
mice that lack one Gdnf allele (Figure 5.4c). Moreover, in dSTR synaptosomal preparations 
signifi cantly higher proportion of DAT was located in the cell surface in mice lacking brain 
GDNF (Figure 5.4d). Hence, endogenous GDNF negatively regulates total DAT protein levels 
and DAT protein levels in synaptosomal membranes explaining the enhanced dopamine uptake 
in Nestin-Cre GDNF cKO mice.
Figure 5.4. Dopamine release and uptake in Nestin-Cre GDNF cKO mice. (a) Th ere were no 
diff erences in single pulse –stimulated dopamine release between the genotypes, when measured by 
cyclic voltammetry in striatal slices. (b) DAT activity, as determined by disappearance of dopamine 
applied to the striatum of anesthetized animals, was enhanced in the absence of brain GDNF. (c) 
Total tissue levels of DAT were clearly increased in dSTR of mice lacking brain GDNF, but also 
slightly increased in C/KO mice consistent with Gdnf gene dose. (d) Biotinylation analysis for surface 
expression of DAT in dSTR synaptosomal preparations indicated that higher proportion of DAT is 
located in the cell surface in F/KO + Nestin-Cre mice. F-fl oxed; KO-knock-out; C-control containing 
both wild-type and fl oxed alleles; DAT-dopamine transporter, GAPDH-glyceraldehyde 3-phosphate 
dehydrogenase. *, **, *** p < 0.05, 0.01 or 0.001 relative to C/C; #, ## p < 0.05 or 0.01 relative to C/KO. 
Kruskal-Wallis test followed by Mann-Whitney U post hoc tests and Bonferroni correction and one-
way ANOVA followed by Student-Newman-Keuls test were used for statistical analysis. Error bars are 
mean ± s.e.m.
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5.6 Brain GDNF expression in GDNF hypermorphic mice 
(Study III)
In GDNF hypermorphic (GDNFh) mice Gdnf mRNA levels are increased in the brain (Figure 
5.5) and elsewhere in the body (Study III, Figure 2C-E, S2C-D), wherever GDNF is natively 
expressed. Analysis of Gdnf mRNA expression suggests that the exact extent of increase is 
dependent on the brain area and the developmental state of the animal (Figure 5.5a, b). In dSTR 
Gdnf mRNA levels were approximately doubled in heterozygous and tripled in homozygous 
animals. In support of this, GDNF protein levels in the adult dSTR were increased to the same 
extent as the mRNA levels (Study III, Figure 3H).
Figure 5.5. GDNF mRNA expression in GDNFh mice. (a) Gdnf mRNA levels at diff erent brain areas 
of GDNFh mice at P7.5. (b) Gdnf mRNA levels at diff erent brain areas of GDNFh adult mice. *, **, *** 
p < 0.05, 0.01 or 0.001 relative to Wt/Wt. One-way ANOVA followed by Student-Newman-Keuls test 
and Student’s t-test were used for statistical analysis. Error bars are mean ± s.e.m.
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5.7 TH+ and VMAT2+ cells in substanƟ a nigra and striatal 
DAT+ varicosiƟ es in GDNF hypermorphic mice (Study III)
In GDNFh mice enhanced Gdnf expression leads to ~15 % increased number of dopaminergic 
cells in SNpc as stereologically estimated by TH+ counting (Figure 5.6a) and confi rmed by 
vesicular monoamine transporter 2 (VMAT2)+ counting (Figure 5.6b). Th e numbers of TH+ 
cells were increased already at P7.5 and remained increased at 3 months of age (Figure 5.6a). In 
dSTR enhanced GDNF expression led to increased number of DAT+ varicosities (Figure 5.6c) 
that represent dopaminergic terminals. DAT+ striatal area was unchanged (Study III, S3I).
Figure 5.6. TH+ and VMAT2+ cell and DAT+ striatal terminal counts in GDNFh mice. (a) 
Unbiased stereological TH+ cell counts indicated higher numbers of dopaminergic cells in mice 
carrying Gdnfh  allele. Th e number of TH+ cells was increased already at P7.5 and remain increased 
in adulthood (3 months) and old age (17 months). (b) Th e number of VMAT2+ cells was increased 
at 3 months of age in GDNFh mice. (c) Unbiased stereological counts for DAT+ varicosities in dSTR 
revealed increased number of dopamine terminals in adult GDNFh mice. TH-tyrosine hydroxylase; 
VMAT2-vesicular monoamine transporter 2;  DAT-dopamine transporter; SNpc-substantia nigra 
pars compacta; dSTR-dorsal striatum. *, ** p < 0.05 or 0.01 relative to Wt/Wt. One-way ANOVA 
followed by Student-Newman-Keuls test and Student’s t-test were used for statistical analysis. Error 
bars are mean ± s.e.m.
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5.8 Monoamine concentraƟ ons in diﬀ erent brain areas of 
GDNF hypermorphic mice (Study III)
In line with the increased number of dopaminergic cells and striatal DAT+ terminals, tissue 
dopamine levels were found to be consistently ~25 % elevated in the dSTR of GDNFh mice 
(Table 5.2). Th is elevation was detected already at P7.5 rostral brain and also in adult GDNFh 
mice (Table 5.2). Furthermore, DOPAC levels were also elevated in dSTR (Table 5.2). In 
vSTR dopamine and DOPAC levels were not signifi cantly elevated (Table 5.2). Th ere were no 
diff erences in dopamine turnover [(DOPAC+HVA)/dopamine] in any brain area (unpublished 
data).
Table 5.2 Cerebral tissue concentrations of dopamine, DOPAC and HVA (ng/g of wet tissue) in 
GDNFh mice at diff erent ages.
P7.5 
Rostral brain
Wt/Wt
Wt/Hyper
Hyper/Hyper
Dopamine
517±22
660±50*
623±31*
DOPAC
41±5
53±8
53±5
HVA
19±4
23±6
27±5
3 months 
Dorsal striatum
Wt/Wt
Wt/Hyper
Ventral striatum
Wt/Wt
Wt/Hyper
Dopamine
***
14 603±525
17 959±378
9 664±281
10 228±396
DOPAC
**
371±31
531±40
326±24
391±38
HVA
P=0.057
143±22
218±31
61±12
76±21
*, **, *** p < 0.05, 0.01 or 0.001 relaƟ ve to Wt/Wt. One-way ANOVA followed by Student-Newman-Keuls test 
and Student’s t-test were used for staƟ sƟ cal analysis. Average ± SEM
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5.9 Dopamine release, uptake and amphetamine responses 
in GDNF hypermorphic mice (Study III)
In dSTR both dopamine release and uptake were increased in GDNFh mice, when measured by 
cyclic voltammetry and in vivo chronoamperometry respectively (Figure 5.7a, b). Remarkably, 
while in chronoamperometry wild-type dopamine uptake rate was quickly saturated, when 
higher amounts of dopamine were ejected to striatum this did not happen in GDNFh mice 
(Figure 5.7b). Enhanced dopamine uptake was accompanied by increased locomotor activity 
and striatal dopamine release in response to amphetamine in GDNFh mice (Figure 5.7c, d). 
Amphetamine also appeared to deplete synaptic dopamine vesicles faster in striatal slices of 
GDNFh mice (Figure 5.7e). Together this indicates that dopamine terminal function in the 
striatum is greatly altered due to higher levels of endogenous GDNF.
Figure 5.7. Dopamine release, uptake and amphetamine responses in GDNFh mice. (a) Striatal 
dopamine terminal stimulation consistently produced higher dopamine peaks in striatal slices of 
GDNFh mice, when measured by cyclic voltammetry. (b) Dopamine uptake was found to be elevated 
in chronoamperometric study, where escalating doses of dopamine were injected to the striatum 
of anaesthetized animals. (c) Amphetamine injection (1 mg/kg; i.p.) caused enhanced locomotor 
response in GDNFh mice compared to their Wild-type littermates.  (d) Local amphetamine 
stimulation caused higher elevation in extracellular dopamine levels in GDNFh mice, when measured 
by in vivo microdialysis in freely moving animals. (e) Amphetamine depleted synaptic dopamine 
vesicles faster in GDNFh mice according to cyclic voltammetry measurements on striatal slices. 
DAT-dopamine transporter. *, **, *** p < 0.05, 0.01 or 0.001 relative to Wt/Wt. One-way ANOVA 
for repeated measures (followed by Bonferroni post hoc test for chronoamperometry) and two-
way repeated measures ANOVA (followed by Sidak´s multiple comparisons in the voltammetric 
amphetamine analysis). Error bars are mean ± s.e.m.
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5.10 Elevated GDNF protects dopamine system from 
lactacysƟ n-induced neurotoxicity (Study III)
As dopamine uptake is 5-fold stronger in GDNFh mice, we found the GDNFh mice to be 5-fold 
more sensitive to DAT-dependent neurotoxin 6-hydroxydopamine (6-OHDA) compared to their 
wild-type littermates (Study III, Figure 4P, Q). So in order to study neuroprotection we needed to 
utilize a model that is independent of DAT function.  We therefore utilized proteasome inhibitor 
lactacystin, which causes accumulation of unfolded proteins and dopaminergic degeneration, 
when injected above SNpc (Bentea et al., 2015). In our experiment unilateral lactacystin delivery 
(4 μg) just above SNpc caused clear side bias in the corridor test (Grealish et al., 2010) 4 weeks 
aft er the injection in wild-type mice but not in their GDNFh littermates (Figure 5.8a).  Consistent 
with our experience that a functional lesion requires at least ~50 % loss in striatal dopamine, the 
dSTR dopamine levels were reduced by ~60 % in wild-type mice and by only ~25 % in GDNFh 
at 5 weeks post lesion (Figure 5.8b). In addition, dopamine metabolites DOPAC and HVA were 
better preserved in GDNFh mice (Study III, Figure 4S). However, the reduction in SNpc TH+ cell 
numbers was approximately the same in both genotypes (30-40 %) (Figure 5.8c). Th is indicates a 
protective or restorative function for endogenous GDNF that still did not save the dopaminergic 
cell bodies that reside in the SNpc (Figure 5.8c).
 
Figure 5.8. GDNFh mice are protected from lactacystin-induced neurotoxicity. (a) 4 weeks aft er 
supranigral lactacystin injection Wild-type mice demonstrated a clear ipsilateral side bias in corridor 
test, while GDNFh mice did not display any bias. (b) 5 weeks aft er lactacystin Wt dopamine levels in 
the dSTR were reduced almost 60 % in the injected side, while in GDNFh mice this reduction was a 
bit over 20 %. (c) Th e number of SNpc TH+ cells was reduced to a similar extent in both genotypes. 
TH-tyrosine hydroxylase; SNpc-substantia nigra pars compacta; dSTR-dorsal striatum. *, p < 0.05 
relative to Wt/Wt. Student’s t-test and repeated measures ANOVA were used for statistical analysis. 
Error bars are mean ± s.e.m.
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Table 5.3. Summary of fi ndings in GDNF cKO and GDNFh adult mice
Measure  GDNF cKO GDNFh
Brain GDNF expression ↓↓ ↑
SNpc dopamine cells ↔ ↑
Striatal dopamine ↔ ↑
Response to amphetamine ↓ ↑
Dopamine release ↔ ↑
Dopamine uptake ↑ ↑↑
Striatal DAT levels ↑ ↔
SensiƟ vity to neurotoxins n.d. ↓
↔ indicates no change, ↑ indicates an increase, ↑↑ indicates a strong increase, ↓ indicates a decrease 
and ↓↓ indicates a strong decrease in comparison to Wild-type littermates. n.d. - not determined.
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6 DISCUSSION
6.1 Role of GDNF in dopamine neuron maintenance during 
development
We found elevated SNpc TH+ cell numbers in P7.5 and adult GDNFh mice, while in Nestin-Cre 
GDNF cKO mice these numbers were unaltered at 3 months of age. Unaltered TH expression 
levels and similarly increased numbers of VMAT2 stained SNpc neurons in GDNFh mice 
suggest that the detected increase is not due to upregulation in TH, but by actual increase in 
dopamine neuron numbers. Th e natural cell death of dopaminergic neurons takes place in two 
apoptotic waves that peak at P2 and P14 in mice (Jackson-Lewis et al., 2000). Th e unaltered 
SNpc dopamine neuron numbers at 3 months old Nestin-Cre GDNF cKO mice suggest that 
GDNF alone is not necessary for the maintenance of these neurons during their development 
and postnatal maturation. However, the increased cell numbers in GDNFh mice indicate that 
endogenous GDNF can aff ect the number of neurons surviving this cell death period. An 
alternative explanation is that GDNF stimulates neurogenesis of dopamine neurons. Hence, it 
appears that other growth factors or some other mechanisms can compensate for the absence of 
GDNF during dopamine neuron development and maturation.
As TH+ cell numbers were already elevated at P7.5 in GDNFh mice and remained similarly 
increased at 3 months of age, it appears that endogenous GDNF plays a role during the fi rst 
but not the second phase of natural cell death. If endogenous GDNF also played a role in the 
second phase, there would have been an even larger diff erence in cell number at 3 months of age 
between GDNFh mice and their wild-type littermates. A specifi c role for GDNF in the fi rst phase 
of natural cell death has been previously suggested based on studies with striatally delivered 
exogenous GDNF (Oo et al., 2003; Kholodilov et al., 2004). In contrast to our study, when GDNF 
was transgenically expressed in the striatum, SNpc TH+ cell numbers were only transiently 
elevated at P7-9 and this increase did not persist to adulthood (Kholodilov et al., 2004). Th is 
diff erence highlights the importance of correct spatial and temporal pattern of GDNF expression 
for its full eff ects.
Our results with the Nestin-Cre GDNF cKO mice are in perfect alignment with the results 
from Nestin-Cre BDNF cKO mice; injection of BDNF neutralizing antibodies to SNpc (Oo et 
al., 2009) or GDNF neutralizing antibodies to dSTR (Oo et al., 2003) at P5-6 both amplify the 
apoptotic cell death of SNpc dopamine neurons. However, the conditional deletion of brain 
BDNF with Nestin-Cre did not have this eff ect (although SNpc organization was disrupted) (Oo 
et al., 2009), similarly to what we report using Nestin-Cre GDNF cKO mice. Furthermore, the 
number of TH+ cells was unchanged in mice with Ret-defi cient dopamine neurons at 3 months of 
age (Kramer et al., 2007), but increased in MEN2B mice with constitutively active Ret (Mijatovic 
et al., 2007). Taken together it appears that the absence of endogenous GDNF, BDNF or Ret can 
be compensated during dopamine neuron development and maturation. However, increasing 
the endogenous GDNF expression or signifi cantly enhancing Ret signaling leads to increased 
numbers of SNpc dopamine neurons surviving the natural cell death period. Th is supports the 
hypothesis that endogenous GDNF functions as a target-derived neurotrophic factor for SNpc 
dopamine neurons during their development, but also indicates that GDNF is not indispensable 
in this role. Th is further suggests that many neurons are responsive for increases in neurotrophic 
factor levels, but not dependent on them, at least of any single one. Th e fact that most intracellular 
pathways are shared between diff erent growth factors is in line with this idea.
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6.2 Impact of endogenous GDNF on striatal dopamine levels 
and release
Similarly to the SNpc dopaminergic cell numbers, the striatal levels of dopamine were elevated in 
GDNFh mice at P7.5 and at 3 months of age, but unchanged in 3 months old Nestin-Cre GDNF 
cKO mice. In 3 months old GDNFh mice dopamine and DOPAC levels were elevated specifi cally 
in dSTR, but not in vSTR. Furthermore, the number of DAT+ terminals was elevated in dSTR of 
GDNFh mice. Together, increased dopamine cell and terminal numbers as well as tissue levels 
of dopamine suggest that stronger GDNF signal leads to an enlarged nigrostriatal dopaminergic 
system. However, an enhanced GDNF signal might additionally stimulate dopamine synthesis 
and storage as happens in MEN2B mice, where the elevation in dSTR dopamine levels is much 
higher than the increase in SNpc TH+ cells or dSTR DAT+ terminal numbers (Mijatovic et al., 
2007). Th is hypothesis is supported by the fact that the dSTR dopamine levels are elevated a bit 
more than the SNpc cell numbers in GDNFh mice (~25 % vs. ~15 %).
Exogenous GDNF reduces TH levels but increases TH phosphorylation leading to enhanced 
dopamine synthesis (Salvatore et al., 2004, 2009). Th erefore, dopamine synthesis in GDNFh 
mice can be increased even though total TH levels were unchanged. VMAT2 packs dopamine 
to synaptic vesicles, so its activity directly aff ects vesicular dopamine content (Eiden and Weihe, 
2011; German et al., 2015), and vesicular packing also relieves TH from the feedback inhibition 
by dopamine (Tekin et al., 2014). Hence, investigating VMAT2 activity and TH phosphorylation 
in GDNFh mice might further resolve the mechanisms of how endogenous GDNF increases 
striatal dopamine levels. Th e results from Nestin-Cre GDNF cKO mice are in line with Ret cKO 
crossed DAT-Cre mice, where the striatal levels of dopamine and its metabolites were similarly 
unaltered (Kramer et al., 2007). In conclusion, higher levels of endogenous GDNF lead to an 
enlarged nigrostriatal dopaminergic system during development and maturation and possibly 
to higher dopamine storage levels in the dorsal striatum. To the contrary, brain GDNF absence 
does not alter the nigrostriatal system size or striatal dopamine levels.
In parallel to dSTR dopamine levels, we found striatal dopamine release unchanged in 
Nestin-Cre GDNF cKO mice, but enhanced in GDNFh mice. Th e tissue dopamine levels most 
likely explain why dopamine release is enhanced in GDNFh mice, but not in Nestin-Cre GDNF 
cKO; as GDNFh mice appear to have more dopamine in the striatal synapses, an electrical 
stimulus would cause more dopamine to be released. Th e increased dSTR tissue levels of the 
dopamine primary metabolite DOPAC suggest that dopamine release is naturally stronger in 
GDNFh mice. Alternatively, increased DOPAC levels may simply refl ect the higher dopamine 
storage levels, which augment vesicular leakage and consequent cytoplasmic metabolism of 
dopamine (Eisenhofer et al., 2004). In support of our data, exogenous GDNF has been shown to 
increase vesicular dopamine content and its subsequent release in vitro (Pothos et al., 1998) as 
well as potassium evoked dopamine release in vivo (Hebert et al., 1996). To test whether increased 
tissue dopamine levels indeed enhanced dopamine release, dopamine release properties could be 
measured also in GDNFh vSTR, where the tissue dopamine levels remained unaltered.
Neurotransmitter-containing vesicles are divided into three major vesicle pools: A readily 
releasable pool, a recycling pool and a reserve pool (Rizzoli and Betz, 2005; Denker and Rizzoli, 
2010). Th e diff erent synaptic pools are in a dynamic balance between each other, but the speed 
of mixing is variable. Studying the absolute and relative changes in the diff erent dopamine 
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vesicle pools in GDNFh mice would uncover how endogenous GDNF aff ects dopamine vesicle 
traffi  cking and recycling. Th is could further explain the mechanisms of increased dopamine 
release. Indeed, results with MEN2B mice suggest them having larger releasable and storage 
pools (representing combined recyclable and release pools) for dopamine (Mijatovic et al., 
2008). However, in MEN2B mice the levels of striatal TH and DAT were elevated and dopamine 
levels increased also in the vSTR (Mijatovic et al., 2007), while in GDNFh mice TH and DAT 
levels were unchanged and vSTR dopamine levels were normal. Th e dopaminergic phenotype 
obviously qualitatively diff ers between GDNFh and MEN2B mice, so direct comparisons should 
be made with caution.
In conclusion, enhanced endogenous GDNF expression increases striatal dopamine release 
most likely refl ecting increased tissue dopamine levels. Absence of brain GDNF has no impact 
on these parameters. 
6.3 Role of GDNF in dopamine neuron maintenance during 
aging
In order to resolve the impact of complete GDNF-defi ciency on midbrain dopamine neuron 
maintenance during normal aging we stereologically estimated SNpc TH+ cell numbers at 14 
and 19 months of age in the GDNF cKO Nestin-Cre line. To our surprise, there was no reduction 
in SNpc TH+ cell numbers in mice lacking one (C/KO) or both (F/KO + Nestin-Cre) Gdnf 
alleles. Th e TH+ cell numbers in VTA were unaltered and the TH-stained midbrain area seemed 
morphologically normal. Moreover, striatal TH+ innervation (optical density) was unchanged in 
the target areas of these neurons, dSTR and vSTR (Study I, Figure 1g). In 17 months old GDNFh 
mice SNpc TH+ cell numbers (P = 0.034) and dSTR dopamine levels (P = 0.0054) were still 
signifi cantly elevated (~10-15 %) compared to wild-type littermates (unpublished results). Th is 
increase is slightly lower in magnitude, compared to the young animals where it was ~15-25 %. It 
suggests that some of the extra neurons these mice had were lost during aging and possibly that 
the eff ects of GDNF on dopamine storage levels were also weakened in old mice. Further studies 
will be needed to resolve this issue. In any case, the enhanced GDNF expression in GDNFh mice 
did not protect additional dopamine neurons from the potential age-related loss compared to 
their wild-type littermates. Together, our data strongly indicate that endogenous GDNF is not 
necessary for the maintenance of midbrain dopamine neurons during aging. Th is is in clear 
contrast with results in (Boger et al., 2006) that reported age-related reduction in TH+ cell 
numbers and TH+ striatal innervation in mice lacking just one functional GDNF allele. However, 
another group did not see these degenerative changes in aged GDNF heterozygous mice or even 
in double heterozygous mice that lacked one allele for both Gdnf and Tgfβ2 (Heermann et al., 
2010). Our results resolve this existing controversy by demonstrating that lifelong lack of one 
or two functional GDNF alleles in the brain does not compromise the integrity of nigrostriatal 
dopamine system during aging. Our fi ndings are in line with the aged Ret cKO mice, where 
degeneration of the nigrostriatal system was moderate at 24 months (38 % TH+ cell loss) 
(Kramer et al., 2007). As Ret serves as a common signaling receptor for all the GDNF family 
ligands (Airaksinen and Saarma, 2002), it is very likely that NRTN for example provided enough 
Ret-mediated trophic support in our GDNF-defi cient mice that the nigrostriatal dopamine 
system maintenance was not compromised.
Discussion
41
All the mouse lines mentioned above carry their GDNF or Ret mutation since early 
embryonic development. Th us, it is possible that developmental compensatory mechanisms 
in the dopamine systems have permanently reduced their inherent dependency on GDNF/
Ret signaling (Ibáñez, 2008). In order to test this hypothesis we utilized two additional cKO 
approaches, where GDNF deletion was induced in young adults (2 months of age) to avoid any 
possible developmental compensation. Unilateral AAV5-Cre injection to the striatum removed 
GDNF specifi cally from the dSTR, which is the innervation target for the SNpc dopamine 
neurons. Gdnf mRNA expression was brought down to almost undetectable levels by 7 months 
post injection, but this did not cause any changes in SNpc TH+ cell numbers or dSTR dopamine 
levels compared to the non-injected side or to the control mice. Similarly, adult Gdnf reduction 
in the Esr1-Cre GDNF cKO line did not aff ect the SNpc TH+ cell numbers.
Our results are in striking contrast with the paper that reported dramatic degeneration in 
both SNpc and VTA dopaminergic cells aft er reducing GDNF just to 40 % of wild-type levels. 
It is important to note that GDNF heterozygous mice, which they and we used as controls, are 
reported to have about 50-60 % of wild-type GDNF levels (Boger et al., 2006; and our published 
and unpublished results). In correspondence Pascual and colleagues recently suggested that it is 
this small drop from 50-60 % to 40 % in GDNF levels that makes the diff erence of life and death 
to brain catecholaminergic neurons. In our Esr1-Cre line GDNF mRNA or protein levels dropped 
down to ~10-15 % of the wild-type levels and even more in 9 months old AAV5-Cre injected mice, 
but there was still no reduction in SNpc dopaminergic cells. To our surprise, the reduction in 
Esr1-Cre GDNF cKO Gdnf mRNA levels appeared to happen independently of TMX injections, 
but still aft er 2 months of age, as at that point there was no reduction yet (Study I, Figure 3b). 
Indeed, the ‘leakiness’ of Cre in Esr1-Cre line has been reported before (Liu et al., 2010) and in 
our case this should not make a signifi cant diff erence as the model achieved its purpose (adult 
reduction in Gdnf expression) and the results were in line with the complementary approach 
with AAV5-Cre. One suggested explanation to the large discrepancy between the two studies 
is the diff erent genetic background of the mice used: C57bl6/129Sv in (Pascual et al., 2008)and 
129Ola/ICR/C57bl6 in our study. Hence, they used a mix of two strains while we used a mix of 
three. Th e possibility of a dramatic background eff ect cannot be ruled out, but one may ask how 
generalizable a result is, if it does not repeat in another mixed mouse line. Another possible, but 
unlikely, explanation is that direct TMX toxicity contributed to the neurodegenerative phenotype 
reported in (Pascual et al., 2008), as the doses administered were high. Further studies will be 
needed to fully resolve this discrepancy. However, together our results indicate that reductions 
in GDNF levels are not associated with dopaminergic degeneration. Th is is supported by the 
fact that mutations in the Gdnf coding region are not commonly contributing to human PD 
pathogenesis, although this might simply be due to lethality of such mutations.
6.4 Eﬀ ects of endogenous GDNF on dopamine uptake
To examine the eff ects of endogenous GDNF on striatal DAT function we studied dopamine 
reuptake and responses to amphetamine stimulation in  GDNF cKO Nestin-Cre and GDNFh 
mouse strains. Both strains had enhanced dopamine reuptake, while amphetamine-stimulated 
hyperlocomotion was reduced in Nestin-Cre GDNF cKO mice and augmented in GDNFh 
mice. Interestingly, while GDNFh mice had no changes in striatal tissue levels of DAT, dSTR 
DAT levels were increased in GDNF cKO Nestin-Cre mice. Moreover, in GDNF cKO Nestin-
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Cre mice a larger fraction of DAT appears to be located in the plasma membrane, where it can 
contribute to the reuptake of extracellular dopamine. Together, increased DAT expression and 
its augmented localization to the plasma membrane likely explain enhanced dopamine uptake 
in the absence of brain GDNF, although other, yet unknown, mechanism(s) may also contribute. 
Even though the cellular localization of DAT has not been determined yet in GDNFh mice, it 
appears that their enhanced DAT function is at least partially due to diff erent mechanism than in 
GDNF cKO Nestin-Cre mice, as discussed below.
Amphetamine increases cytosolic dopamine levels by releasing dopamine from the storage 
vesicles, which eventually induces DAT-mediated dopamine effl  ux to the extracellular space 
(German et al., 2015). Amphetamine also directly inhibits DAT function (German et al., 2015), 
which contributes to the increased extracellular dopamine levels and resulting hyperlocomotion. 
It appears that amphetamine had fundamentally diff erent eff ects in the two GDNF mouse strains. 
In GDNFh mice amphetamine depleted dopamine from the storage vesicles faster, while in 
Nestin-Cre GDNF cKO mice this aspect was unchanged (Study II, Figure 1E). Th is suggests that 
GDNFh vesicles contain more dopamine and their VMAT2 function is enhanced. In Nestin-Cre 
GDNF cKO line amphetamine-induced dopamine effl  ux was clearly reduced, mostly because 
their DAT was much slower to reverse its transport direction (reduced DAT reversal time). Th is 
could be because the larger surface DAT population would respond slower to amphetamine, if a 
signifi cant fraction of DAT molecules remained in the uptake transport mode. In GDNFh mice, 
DAT reversal time appeared to be unchanged (unpublished data). Finally, in vivo microdialysis 
showed enhanced extracellular dopamine levels aft er amphetamine stimulation in GDNFh mice 
(published), but no diff erences in GDNF cKO Nestin-Cre (unpublished data).
Together these results suggest that altered locomotor response to amphetamine in the 
two mouse strains (increased in GDNFh and decreased in GDNF cKO Nestin-Cre) is due to 
diff erent mechanisms. In GDNFh mice it may have been due to faster dopamine depletion from 
the storage vesicles and in Nestin-Cre GDNF cKO because of slower DAT reversal or otherwise 
altered DAT function. Th e reduced DAT reversal time in GDNF cKO Nestin-Cre only, further 
suggests that even though dopamine reuptake was robustly increased in both mouse models, 
the underlying mechanism was diff erent. For example, in GDNFh mice increased DAT activity 
may simply be a secondary compensatory mechanism to increased dopamine release. On the 
other hand, both PI3K/Akt and MAPK pathways that are downstream from Ret, are known to 
positively regulate DAT function (Eriksen et al., 2010).
Literature suggests several more direct interactions and relationships between GDNF and 
DAT, probably refl ecting the complexity of their interaction. Already the fi rst GDNF article 
reported that exogenous GDNF stimulates dopamine uptake in cultured embryonic dopamine 
neurons (Lin et al., 1993). In contrast, a recent study reported that GDNF/Ret signaling reduces 
DAT in vitro and in vivo activity by promoting its removal from the plasma membrane (Zhu 
et al., 2015). Th is interaction was reported to depend on endocytosis mediator Vav2, as Ret 
activation enhanced binding between Vav2 and DAT, and to be specifi c for vSTR (Zhu et al., 
2015). In another recent study viral over-expression of GDNF in dSTR reduced dopamine 
uptake (Barroso-Chinea et al., 2016). Decrease in DAT activity was reported to be associated 
with DAT-DAT interactions and DAT interactions with α-synuclein (Barroso-Chinea et al., 
2016). Interestingly, increased DAT activity has been reported in MEN2B mice with greatly 
enhanced Ret signaling (Mijatovic et al., 2008) as well as in mice heterozygous for GDNF (Littrell 
et al., 2012) and Ret (Zhu et al., 2015). Finally, it is important to note that we did not observe 
signifi cantly increased dopamine uptake in heterozygous C/KO mice that served as controls in 
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our study. Our data suggests that absence of one Gdnf allele is not suffi  cient to alter DAT activity, 
although DAT expression was slightly increased. 
It is possible that several of the previously identifi ed mechanisms are in a complex interplay 
in our mouse lines resulting in enhanced dopamine uptake aft er both abolished and enhanced 
GDNF expression. In contrast to Zhu et al. we found DAT cell surface localization increased 
in dSTR, but unchanged in vSTR (unpublished data), while they reported completely opposite 
eff ect in Ret heterozygous mice (Zhu et al., 2015). Th e apparent complexity and importance of 
the GDNF/DAT relationship calls for further research. Another factor that potentially confounds 
the resolution of GDNF’s role in DAT regulation is that in GDNFh and Nestin-Cre GDNF cKO 
mice GDNF expression is changed since the early embryonic stage. Th is can cause fundamental 
alterations in midbrain dopamine systems during their development and maturation, which may 
infl uence DAT function in the adult animals. In order to diff erentiate between developmental 
and direct GDNF eff ects, the reduction or increase in endogenous GDNF levels should be 
induced in mature adult animals, for example by AAV5-Cre injection.
In conclusion, both increase and decrease in endogenous GDNF expression lead to 
enhanced dopamine uptake by apparently diff erent mechanisms. However, locomotor response 
to amphetamine appears to parallel changes in endogenous GDNF expression, but also here the 
mechanism is likely diff erent in the two mouse models. Th e complex interaction between GDNF 
and DAT most likely contributes to these phenotypes. Further research is required to resolve 
the eff ects of endogenous GDNF on dopamine uptake and on dopamine terminal function in 
general.
6.5 Role of endogenous GDNF in neuroprotecƟ on
As dopamine uptake was greatly enhanced in GDNFh mice we could not use the traditional 
dopaminergic neurotoxins like 6-OHDA and MPTP to study neuroprotection, as their toxicity 
to dopamine neurons is dependent on DAT activity (Duty and Jenner, 2011). In line with that 
expectation, GDNFh mice had enhanced sensitivity to striatal 6-OHDA injection (Study III, 
Figure 4P-Q) and therefore we needed to utilize a neurotoxin whose eff ects are DAT-independent. 
We chose proteasome inhibitor lactacystin, whose toxicity is based on inhibition of proteasomal 
protein metabolism and subsequent cellular accumulation dysfunctional proteins (Duty and 
Jenner, 2011). Th is mechanism appears to bear direct relevance to human PD pathology, where 
accumulation and spread of proteinous Lewy bodies seems to play a key role (Meissner et al., 
2011; Goedert et al., 2013).
Four to fi ve weeks aft er supranigral lactacystin delivery, GDNFh mice exhibited no motor 
function impairment in corridor test and better-preserved dopamine levels in dSTR compared to 
their wild-type littermates. However, SNpc TH+ cells were similarly reduced in both genotypes. 
Th is suggests that endogen0us GDNF is able to protect or regenerate striatal dopaminergic fi bers, 
but does not protect the nigral cell bodies. Th ere are several mutually non-exclusive explanations 
for the higher dSTR dopamine levels we observed 5 weeks post lesion: Increased endogenous 
GDNF expression either helped more dopaminergic fi bers to survive the toxic insult, promoted 
their sprouting and recovery aft er the acute lesion or stimulated dopamine production in the 
remaining terminals. Results from MPTP lesioned Ret cKO mice support the second hypothesis, 
as there was no diff erence in the initial lesion severity, but the Ret-defi cient dopamine neurons 
were incapable for axonal resprouting (Kowsky et al., 2007). On the other hand, constitutively 
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active Ret was reported to be protective for SNpc cell bodies but not for axonal terminal in 
MEN2B mice (Mijatovic et al., 2011). However, those studies were conducted using 6-OHDA 
and MPTP in MEN2B mice that have greatly enhanced DAT activity (Mijatovic et al., 2008). In 
the light of our data with 6-OHDA in GDNFh mice, it is very likely that the MEN2B response 
to those toxins was a combination of increased sensitivity and a massive trophic signal through 
constitutively active Ret. To test this hypothesis, MEN2B mice should be studied in the same 
lactacystin model we used with GDNFh mice.
To further resolve the nature of the protective/restorative eff ect in GDNFh mice, the 
animals should be analyzed at one week aft er lactacystin injection, as at that point lactacystin 
lesion appears to be fully developed (Bentea et al., 2015), but possible axonal resprouting has not 
happened yet (Kowsky et al., 2007). In addition, Nestin-Cre GDNF cKO mice should be studied 
in the lactacystin model to fi nd out whether brain GDNF absence predisposes the nigrostriatal 
dopamine system to its toxic eff ects.
In summary, endogenous GDNF displays clear functional and neurochemical benefi ts in the 
lactacystin-based Parkinson’s disease model, but the exact mechanisms remain to be resolved.
6.6 General discussion
We found brain Gdnf mRNA expression to be either undetectable or very low in the GDNF 
cKO strains (Nestin-Cre, AAV5-Cre and Esr1-Cre) and moderately increased in the GDNFh 
mice. From that perspective, the models are opposite to each other and we naturally expected 
them to have opposite phenotypes. However, the only opposite phenotype we have found so 
far is the locomotor response to amphetamine and also in this case the mechanism appears to 
diff er between these models. In most of the core dopamine system measures GDNFh mice had 
a phenotype, but the GDNF cKO mice did not. An important exception were amphetamine 
responses and striatal dopamine uptake, which are at least partially related.
Similarly to our fi ndings with GDNF cKO Nestin-Cre mice, mutant mice for PD-related 
genes α-synuclein, leucine-rich repeat kinase 2 (LRRK2), Parkin, DJ-1 and PTEN-induced 
kinase 1 (PINK1) exhibit changes in dopamine release or uptake without accompanying loss of 
dopaminergic neurons or striatal dopamine content (Reviewed in Rice et al., 2011). It seems that 
a single mutation in one of these factors is not suffi  cient to cause a full parkinsonian phenotype, 
but maybe requires a “second hit”. It is also possible that brain GDNF absence predisposes to 
neurodegeneration if combined with an adequate additional genetic or environmental stressor, as 
has been shown for Ret-defi cient mice (Aron et al., 2010; Meka et al., 2015). Also in α-synuclein 
overexpressing mice dopamine neurotransmission is altered prior to dopamine neuron loss 
(Janezic et al., 2013).
However, in the big picture our data strongly suggests that at least some of the potential 
consequences of brain GDNF absence are compensated for, thus leading to a dampened 
phenotype. Th ese sorts of limitations of the knock-out approach have been acknowledged for 2o 
years (Routtenberg and Gerlai, 1996). Th e fact that signaling receptor Ret is shared with all the 
GDNF family members is likely to explain why Ret-defi cient mice have a stronger phenotype than 
GDNF cKO mice. However, trophic intracellular signaling pathways, like PI3K/Akt and ERK/
MAPK, are not specifi c to Ret, and hence it is very likely that neurons can partially compensate 
for the reduced Ret signal from other sources. Recent evidence suggests that dopamine neurons 
can dynamically infl uence the amount of striatal GDNF available for them (Gonzalez-Reyes et 
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al., 2012). In the absence of GDNF/Ret, they might be able to stimulate secretion of some other 
trophic factor to maintain their survival and function. Moreover, it is safer for the neurons not to 
rely on a single source of survival signals during their lifecycle. Th e apparent limitations of gene 
ablation strategy call for novel animal models to study gene function.
Th e GDNFh strain indeed appears to be more informative regarding the role and functions 
of endogenous GDNF. Contrarily to reductions in GDNF expression, nigrostriatal dopaminergic 
neurons appear to be sensitive to a moderate increase in endogenous GDNF levels. Th is is also 
in contrast with various studies using GDNF delivery or viral overexpression of up to more than 
100 fold over the natural expression levels. Our results suggest that the correct spatiotemporal 
pattern is more important for GDNF eff ects than the total amount of GDNF protein delivered 
to the tissue. Very strong overexpression can be expected to produce various adverse-eff ects 
that are not necessarily related to the natural GDNF signal. In line with this, increased levels of 
endogenous GDNF indeed did not elicit side-eff ects reported with ectopic GDNF applications, 
such as hyperactivity (Hudson et al., 1995; Hebert et al., 1996; Hebert and Gerhardt, 1997) or 
reduced food intake and weight loss (Hudson et al., 1995; Manfredsson et al., 2009) (Study 
II, Figure 4U-W). Th is suggests that elevation of endogenous GDNF might be a viable future 
strategy for treating PD. However, more basic research is needed fi rst to understand its full 
potential and limitations. Th e ongoing studies with conditional GDNF hypermorphs (or GDNF 
“knock-up” mice), where GDNF 3’UTR replacement can be induced in adult animals, will be an 
important milestone in this path.
Results with GDNFh mice suggest that endogenous GDNF plays an important role in 
the development, function and protection of these neurons. Our data also indicates that in 
vivo studies using ectopic GDNF do not reliably or comprehensively predict the functions of 
endogenous GDNF (Study III, Table 1). However, even though we have clearly demonstrated 
the potential value of 3’UTR replacement method, it has its own limitations as well. Th e native 
3’UTR might contain important signals for processing and cellular localization that will be lost 
upon replacement. In any case, the potential extent of misexpression would be minor compared 
to viral vector delivery or conventional overexpression models. Th e extent of the target gene 
derepression also depends on the amount of destabilizing miRNAs and RNA binding proteins 
present in each tissue. Finally, 3’UTR replacement is not feasible for many genes as already 
Gfrα1, 3 and 4 do not appear to contain miRNA binding sites (unpublished data). Regardless of 
its limitations, 3’UTR replacement method is likely to greatly advance the understanding of in 
vivo functions of many important genes.
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7 CONCLUSIONS
Th e aim of these studies was to gain insight into the role of endogenous GDNF in the 
development, function and maintenance of midbrain dopamine neurons. Th e principal fi ndings 
of the study are:
1. Endogenous GDNF functions as a target-derived neurotrophic factor for SNpc 
dopamine neurons during their development and maturation, but it is not indispensable 
in this role. Augmented endogenous GDNF expression leads to larger nigrostriatal 
dopamine system during development.
2. Endogenous GDNF alone is not required for the maintenance of midbrain dopamine 
neurons during aging.
3. Elevated levels of endogenous GDNF lead to increased dopamine content and dopamine 
release in the dSTR, whereas brain GDNF absence had no eff ect on them. Both an 
increase and a decrease in GDNF expression lead to enhanced dopamine uptake.
4. Augmented endogenous GDNF expression provides clear functional and neurochemical 
protection in a neurotoxin-based Parkinson’s disease model.
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